NOTICE UNDER SECTION 26 OF THE
PATENTS LAW, 5727-1967
The applications, particulars of which are set
out below, have been accepted pursuant to
Section 17 of the Patents Law. Any person
wishing to oppose the grant of a patent on any
of the applications published here, may,
within three months from the date of this
journal, give to the Commissioner of Patents
notice under Section 30 of the Patents Law, in
the manner prescribed in regulations 57 et seq
of the Patents Regulations, 5728-1968
Particulars of the applications, where
applicable, are given in the following order:
[11] [21] Number of application
[54] Title of invention
[22] Application date
[31] [32] [33] Number and date of foreign
application – convention country.
*[51] Int.Cl.
[61] Application for patent of addition
[62] Divisional application
[71] Applicant
[72] Inventor
[87] International Publication Number
[74] Address for service
[57] Abridgement of invention (in the
language in which the specification is drawn
up)
*Note: As from Patents and Designs Journal
No.1/06, patent applications are classified
according to the Eighth Edition of the
International Patent Classification (2006)
]22[]12[
- ‫ לחוק הפטנטים תשכ"ז‬62 ‫הודעה לפי סעיף‬
6792
‫הבקשות שפרטיהן מתפרסמים להלן קובלו‬
‫ כל המעונין‬.‫ לחוק הפטנטים‬69 ‫לפי סעיף‬
‫להתנגד למתן פטנט על פי בקשה מהבקשות‬
‫ תוך שלושה חדשים‬,‫המתפרסמות רשאי‬
‫ להגיש לרשם הפטנטים‬,‫מתאריך יומן זה‬
‫ לחוק‬03 ‫הודעת התנגדות לפי סעיף‬
‫ ואילך‬79 ‫הפטנטים בדרך הקבועה בתקנה‬
.6721 – ‫ תשכ"ח‬,‫לתקנות הפטנטים‬
‫פרטי הבקשות במידה ויישימים מובאים לפי‬
:‫סדר זה‬
‫מספר הבקשה‬
‫שם האמצאה‬
‫תאריך הבקשה‬
‫מספר ותאריך של בקשות החוץ – מדינת‬
‫האגוד‬
‫*סיווג בינלאומי – מהדורה שביעית‬
‫בקשה לפטנט מוסף‬
‫בקשת חלוקה‬
‫המבקש‬
‫הממציא‬
‫מס' פרסום של בקשה הבינלאומית‬
‫מען למסירת מסמכים‬
)‫תקציר האמצאה (בשפה בה ערוך הפירוט‬
'‫ החל מיומן הפטנטים והמדגמים מס‬:‫*הערה‬
‫ ניתן ציון לבקשות פטנטים הסיווג לפי‬6032
‫המהדורה השמינית של הסיווג הבינלאומי‬
)6332 ‫של פטנטים (משנה‬
767101
TNF ‫אפנון פעולת הקולטן של‬
]45[
TNF RECEPTOR ACTION
MODULATION
]11[
]42[
]12[
03.05.1992
Int. Cl.8 C07K 014/525, 014/715, 016/24, 016/28, C12N 015/12
YEDA RESEARCH AND
‫ רחובות‬,‫ידע חברה למחקר ופיתוח בע"מ‬
DEVELOPMENT CO. LTD.
February 11, 2007 – ‫כ"ג בשבט התשס"ז‬
4358
]15[
,‫אינטר לאב בע"מ‬
‫ נס ציונה‬,‫קרית ויצמן‬
INTERLAB LTD.,,
KIRYAT WEIZMANN
NES ZIONA 76110
[57] A method for identifying molecules
which interfere with the normal
functioning of the TNF-R comprising:
(a) providing a target peptide which is
represented by the amino acids 170-174,
175-179, 170-179 or 405-414 of human
p55-TNF-R as shown in Fig 1 of the
specification,
(b) contacting said target peptide with a
candidate molecule from a peptide library,
from a library of synthetic organic
molecules or with bacterial culture
products, fungi culture products,
eukaryotic culture products or crude
cytokine preparations, and
(c) identifying a molecule which binds to
said target peptide.
‫ לתקנות‬53 ‫פירוט זה נבחן בהתאם לתקנה‬
8691 – ‫ תשכ"ח‬,‫הפטנטים‬
This specification was examined in
accordance with regulation 35 of the Patent
Regulations, 5728 - 1968
__________
]22[]12[
]45[
METHOD AND APPARATUS FOR
COOLING HOT FLUIDS
]11[
]32[
]42[
]12[
08.02.1994
017302
]31[ 12.02.1993
Int. Cl.8 F01K 023/04
ORMAT TECHNOLOGIES INC.,
U.S.A.
Y. BECK,
P.O.B. 68, YAVNE 70650
]15[
[57] Apparatus (40) for cooling a hot
fluid comprising:
(a) a heat exchanger (43) adapted to
receive said hot fluid and liquid coolant for
cooling the hot fluid and vaporizing the
liquid coolant;
(b) a turbine (47) having an output shaft
connected to a fan (49), and responsive to
vaporized coolant for driving the fan to
blow air, and producing vaporized coolant
which exits the turbine;
(c) a condenser (50) for receiving
4359
760800
‫שיטה והתקן לקירור זורמים חמים‬
]33[
US
,‫ בהק‬.‫י‬
‫ יבנה‬,21 .‫ד‬.‫ת‬
vaporized coolant that exits the turbine,
and responsive to air blown by the fan for
condensing the vaporized coolant received
in the condenser into coolant condensate;
and
(d) means (51) for returning the coolant
condensate to said heat exchanger;
(e) wherein the fan is provided with a
rotation responsive air brake control for
controlling the amount of air blown by the
fan in response to its rotation.
__________
]22[]12[
770670
RNA ‫שושלות תאים אאוקריוטיים לאיכסון‬
‫ באמצעות‬,‫רטרו נגיפי רקומביננטי‬
‫השלמת טרנס ווקטורי הבעה המשמשים‬
‫להשלמת הטרנס‬
]45[
EUKARYOTIC CELL LINES FOR
PACKAGING RECOMBINANT
RETROVIRAL RNAS BY
TRANSCOMPLEMENTATION,
AND EXPRESSION VECTORS FOR
USE IN SAID
TRANSCOMPLEMENTATION
]11[
]32[
]42[
]12[
30.11.1995
9414406
]31[ 30.11.1994
]33[ FR
Int. Cl.8 C12N 005/10, 015/09, 015/48, 015/867
ODILE COHEN-HAGUENAUER,
FRANCE
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל אביב‬,0323 .‫ד‬.‫ ת‬, 66 ‫רחוב אחד העם‬
P.O.BOX 4060,
TEL AVIV 61040
]15[
[57] A cultured eukaryotic cell exhibiting
the following properties: the cell is
selected from a dog, the cell has a
homogeneous morphology that is stable
over time, the cell is not of tumor origin,
the cell is selectable in a minimum culture
medium lacking CO2, without prior
transformation, and the cell exhibits
accelerated kinetics, wherein the cell is
suitable for packaging recombinant
retroviral RNAs by transcomplementation.
__________
]22[]12[
]45[
REDUCTION OF INFARCT
VOLUME USING CITICOLINE
]11[
]32[
05.03.1996
399262
]31[
06.03.1995
February 11, 2007 – ‫כ"ג בשבט התשס"ז‬
771766
‫הפחתת נפח אוטם באמצעות ציטיכולין‬
]33[
US
4360
]42[
]12[
]11[
]15[
213211
1121122002
US
Int. Cl.8 A61K 031/66, 031/70, A61P 025/00, C07H 019/00
FERRER INTERNACIONAL S.A.,
SPAIN
BOBBY W. SANDAGE, JR., MARC
FISHER, KENNETH W. LOCKE
DR. SHLOMO COHEN,
,'‫ד"ר שלמה כהן ושות‬
IBN GVIROL 124
‫אביב‬-‫ תל‬,660 ‫אבן גבירול‬
TEL AVIV 62038
[57] Use of citicoline or a
pharmaceutically acceptable salt thereof,
excluding cytidine
diphosphoethanolamine, cytidine
diphospho-N-methylethanolamine and
cytidine diphospho-N,NThe applications for division
from this application have
not yet been published
dimethylethanolamine, for the preparation
of a medicament for protecting brain tissue
from cerebral infarction subsequent to an
ischemic event, substantially as described
in the specification.
,871711
‫בקשות חלוקה מבקשה זו‬
.‫שטרם פורסמו‬
__________
]22[]12[
]45[
]11[
]42[
]12[
]11[
CUTTING INSERT
30.06.1998
Int. Cl.8 B23B 001/00, 027/16, 027/18
ISCAR LTD.
AMIR SATRAN, RAFAEL
MARGULIS
]15[ ISCAR LTD.,
P.O. BOX 11
TEFEN 24959
[57] A cutting insert (1) for mounting on
a cutting tool, comprising: a front cutting
portion (2) having an operative front
surface (3) associated with at least one
cutting edge (6, 7) and a trailing mounting
portion (4) having upper, lower (12) and
side (13) walls extending from said front
cutting portion to a rear abutment wall (14)
of the trailing mounting portion oriented
generally co-directionally with said
operative front surface, the side walls of
the trailing mounting portion meeting with
4361
768771
‫שימת חיתוך‬
‫ תפן‬,‫ישקר בע"מ‬
‫ רפאל מרגוליס‬,‫אמיר סטרן‬
,‫ישקר בע"מ‬
‫ תפן‬,66 .‫ד‬.‫ ת‬,
said rear abutment wall at rear edges (15);
said rear abutment wall comprising two
lateral surfaces (20) and a central surface
(22) therebetween, said lateral surfaces
converging from said rear edges in the
direction towards the front cutting portion,
and said central surface protruding, in the
direction away from said front cutting
portion, outwardly from adjacent portions
of the lateral surfaces and meeting
therewith at merging edge regions (23).
__________
]22[]12[
]45[
OPTICAL DISC SYSTEM
]11[
]32[
18.01.1996
376882
]31[
25.01.1995
February 11, 2007 – ‫כ"ג בשבט התשס"ז‬
761071
‫מערכת דיסק אופטית‬
]33[
US
4362
]42[
]21[
]12[
]15[
Int. Cl.8 G11B 007/00
DIVISION FROM 116805
DISCOVISION ASSOCIATES, U.S.A.
REINHOLD COHN AND
PARTNERS,
21 AHAD HA'AM ST.,
P.O.BOX 4060,
TEL AVIV 61040
[57] In an optical disc system, the
combination comprising: first means
(Q301-Q306) for passing electrical current
to a laser; second means for setting a
reference voltage on said first means; third
means (U301A, U302B) for applying a
drive voltage to said first means, said drive
voltage having a first voltage level and a
second voltage level, said third means
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,0323 .‫ד‬.‫ ת‬, 66 ‫רחוב אחד העם‬
supplying said electrical current only when
said drive voltage is at said first voltage
level; and fourth means (7-506, 7-507) for
switching said first voltage level and said
second voltage level so that electrical
power is consumed when said laser is
energized and enhanced rise and fall
switching characteristics are achieved.
__________
]22[]12[
]45[
HOMING GIMBAL SYSTEM
]11[
]42[
]12[
29.12.1998
Int. Cl.8 G01S 005/00
RAFAEL-ARMAMENT
DEVELOPMENT AUTHORITY
4363
761060
‫מערכת גימבלי לביות‬
,‫רפא"ל רשות לפיתוח אמצעי לחימה בע"מ‬
]71[
]15[
LTD.
WO/1998/032411
DR. MARK FRIEDMAN LTD.,
BEIT SAMUELOFF, 7 HAOMANIM
STREET
TEL AVIV
[57] A homing gimbal system (50)
characterized by high spatial stability,
wide field of regard and large mounted
apertures, the system comprising:
(a) a first gimbal (52) rotating around a
first axis for homing in a first axial
direction (54);
(b) an intermediate gimbal (56) being
pivotally connected in a first connection to
said first gimbal, said intermediate gimbal
rotating around a second axis (62), said
‫חיפה‬
,‫ד"ר מרק פרידמן ושות‬
‫ תל אביב‬,9 ‫בית שמואלוב רח' האומנים‬
second axis being orthogonal to said first
axis for homing in a second axial direction,
said second axial direction being
orthogonal to said first axial direction; and
(c) a payload (64) being pivotally
connected to said intermediate gimbal, said
payload rotating around a third axis (58),
said third axis being orthogonal to said
second axis for further homing in a third
axial direction.
__________
]22[]12[
]45[
USE OF PHARMACEUTICAL
COMPOSITIONS COMPRISING A
SELECTIVE EP2 RECEPTOR
SUBTYPE AGONIST IN THE
PREPARATION OF
MEDICAMENTS FOR
February 11, 2007 – ‫כ"ג בשבט התשס"ז‬
716111
‫שימוש בתכשירי רוקחות המכילים‬
‫אגוניסטים סלקטיביים לתת–סוג של‬
‫ בהכנת תרופות למניעת דלדול‬EP2 ‫קולטן‬
‫ הגדלת מסת עצם וטיפול בהפרעות‬,‫עצם‬
‫הקשרוות למסת עצם נמוכה‬
4364
PREVENTING BONE LOSS,
AUGMENTING BONE MASS AND
TREATING CONDITIONS WHICH
PRESENT LOW BONE MASS
]11[
]32[
]42[
]12[
]71[
]15[
27.11.1997
60/033569
]31[ 20.12.1996
]33[ US
Int. Cl.8 A61K 031/10, 031/18, 031/185, 031/38, 031/41, A61P 019/08, C07C 059/76,
059/90, 311/04, 317/04, 323/32, C07D 233/16, 257/04, 333/40
PFIZER INC., U.S.A.
WO/1998/027976
LUZZATTO & LUZZATTO,
,‫לוצאטו את לוצאטו‬
INDUSTRIAL PARK, OMER
‫ באר שבע‬,7076 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
P.O.B 5352
BEER-SHEVA 84152
[57] Use of a therapeutically effective
amount of a selective EP2 receptor subtype
agonist in the preparation of a medicament
for preventing bone loss and augmenting
bone mass in a mammal, substantially as
described in the specification.
__________
]22[]12[
717110
‫תהליך לייצור הדרזידים מותמרים תוך‬
‫שימוש בחומצות קרבוקסיליות‬
]45[
PROCESS FOR PREPARING
SUBSTITUTED HYDRAZIDES
USING CARBOXYLIC ACIDS
]11[
]32[
]42[
]12[
]15[
13.08.1999
60/098059
]31[ 27.08.1998
]33[ US
Int. Cl.8 C07C 241/02, 243/00, 243/08, 243/34
DOW AGROSCIENCES LLC, U.S.A.
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל אביב‬,0323 .‫ד‬.‫ ת‬, 66 ‫רחוב אחד העם‬
P.O.BOX 4060,
TEL AVIV 61040
[57] A process comprising the reaction of
a carboxylic acid or salt thereof with
4365
hydrazine or salt or hydrate thereof, or a
substituted hydrazine or salt or hydrate
thereof in the presence of a triazine
substituted with at least one chloro or
fluoro to produce a hydroxytriazine and a
monoacylhydrazine or substituted
monoacylhydrazine according to the
reaction
wherein
R1 is a hydrogen atom, (C1-C8) alkyl, cyclo
(C5-C6) alkyl, naphthyl, phenyl, phenyl
substituted with from one to three
substituents independently selected from
(C1-C4) alkyl, (C1-C4) alkoxy, (C1-C2)
alkoxy (C1-C2) alkyl, (C1-C4) alkylthio,
halo and cyano, 5-methyl-6-chromanyl,
furyl, thienyl, pyridyl or benzyl, R2 is (C1C4) alkyl, phenyl, phenyl substituted with
from one to three substituents
independently selected from (C1-C4) alkyl,
(C1-C4) alkoxy, (C1-C2) alkoxy (C1-C2)
alkyl, (C1-C4) alkylthio, halo and cyano,
benzyl or phenethyl, R3, R4 and R5 are
each independently selected from a
hydrogen atom, (C1-C8) alkyl, cyclo (C5C6) alkyl, phenyl, phenyl substituted with
from one to three substituents
independently selected from (C1-C4) alkyl,
(C1-C4) alkoxy, (C1-C2) alkoxy (C1-C2)
alkyl, (C1-C4) alkylthio, halo and cyano,
benzyl or phenethyl, M is a hydrogen atom
or a metal cation selected from sodium,
potassium, lithium, calcium, cesium and
barium, n is 1 or 2, X is fluoro or chloro,
each Y is independently selected from
fluoro, chloro, R2 and OR2, and each Z is
independently selected from hydroxy, R2
and OR2.
__________
]22[]12[
]45[
COMPOSITIONS FOR
TREATMENT OF DISORDERS
INVOLVING PROGRAMMED
CELL DEATH
717710
‫הרכבים לטיפול באי–סדר הקשור למוות‬
‫תאי מתוכנן‬
]11[
]32[
]42[
]12[
03.03.1998
810712
]31[ 03.03.1997
]33[ US
Int. Cl.8 A61K 048/00, C07K 014/47, C12N 009/64, 015/11, 015/12, C12Q 001/68
YEDA RESEARCH AND
‫ רחובות‬,‫ידע חברה למחקר ופיתוח בע"מ‬
DEVELOPMENT CO. LTD.
]71[ WO/1998/039429
]15[ REINHOLD COHN AND
,‫ריינהולד כהן ושותפיו‬
PARTNERS,
‫ תל אביב‬,0323 .‫ד‬.‫ ת‬, 66 ‫רחוב אחד העם‬
21 AHAD HA'AM ST.,
P.O.BOX 4060,
TEL AVIV 61040
inducing programmed cell death, in the
preparation of a pharmaceutical
[57] Use of a therapeutically effective
composition for use in the treatment of
amount of an expression vector comprising
metastasizing tumor cells.
SEQ ID NO. 3 DNA sequence capable of
February 11, 2007 – ‫כ"ג בשבט התשס"ז‬
4366
__________
]22[]12[
]45[
PHOTOCATALYTICALLYACTIVATED SELF-CLEANING
ARTICLE AND METHOD OF
MAKING SAME
]11[
]32[
12.03.1998
60/040566
]31[ 14.03.1997
700141
1321122001
Int. Cl.8 C03C 017/245, 017/25, 017/34
PPG INDUSTRIES OHIO, INC.,
U.S.A.
WO/1998/041480
SANFORD T.COLB & CO.,
P.O.B. 2273,
REHOVOT
]42[
]12[
]71[
]15[
[57] A method comprising the steps of:
manufacturing a continuous glass float
ribbon having a first major surface and an
opposite major surface defined as a second
major surface, the first major surface
having tin diffused therein characteristic of
forming the glass float ribbon on a molten
tin bath, positioning a chemical vapor
deposition coating apparatus over the
surface of the float ribbon at a point in the
manufacture of the float ribbon where the
float ribbon has a temperature of a least
about 400o C; directing a metal oxide
precursor selected from the group
717101
‫חפץ המתנקה מעצמו המופעל ע"י זרז אור‬
‫ושיטה לייצורו‬
]33[
US
US
,,'‫ קולב ושות‬.‫סנפורד ט‬
‫ רחובות‬,6690 .‫ד‬.‫ ת‬, ‫ מרמורק‬,0 ‫שער הגיא‬
consisting of titanium tetrachloride,
titanium tetraisopropoxide and titanium
tetraethoxide in a carrier gas stream
through said chemical vapor deposition
apparatus over a surface of the float ribbon
and annealing the float ribbon to produce
titanium dioxide in the crystalline phase as
a photocatalytically-activated self-cleaning
coating over the glass float ribbon,
whereby said coating has a
photocatalytically-activated self-cleaning
reaction rate of least about 2x10-3 cm-1
min-1.
__________
]22[]12[
]45[
4367
METHOD FOR THE
PRODUCTION OF ANTI-HUMAN
ANTIGEN RECEPTORS AND USES
THEREOF
716606
‫שיטה ליצור קולטנים כלפי אנגד של בני‬
‫אדם‬
]11[
]32[
]42[
]12[
]71[
]15[
14.04.1998
97106109.8
]31[ 14.04.1997
]33[ EP
Int. Cl.8 A61K 039/395, C07K 016/00, 016/30, C12N 015/13
MICROMET AG, GERMANY
WO/1998/046645
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל אביב‬,0323 .‫ד‬.‫ ת‬, 66 ‫רחוב אחד העם‬
P.O.BOX 4060,
TEL AVIV 61040
[57] A method for the production of an
anti-human antigen receptor that is low or
not immunogenic in humans, the method
comprising a step of selection of a
combination of functionally rearranged
VH and VL immunoglobulin chains,
characterized in that at least the VH chain
is derived from unprimed mature human
B-lymphocytes, and the VL chain is
derived from a naturally occurring human
B cell repertoire, said chains being
expressed from a recombinant vector and
by using for the selection an in vitro
display system for binding to a human
antigen.
__________
]22[]12[
716016
,‫ החלבון‬,GILR ‫ המקודד עבור חלבון‬DNA
‫הכנתו והשמוש בו‬
]45[
DNA ENCODING A GILR
PROTEIN, THE PROTEIN, ITS
PREPARATION AND USE
]11[
]32[
]42[
]12[
27.04.1998
971070339
]31[ 28.04.1997
]33[ EP
Int. Cl.8 A61K 038/17, 048/00, C07K 014/47, C12N 015/12
APPLIED RESEARCH SYSTEMS
ARS HOLDING N.V.,
NETHERLANDS ANTILLES
WO/1998/049291
INTERPHARM LABORATORIES
,‫אינטרפארם מעבדות בע"מ‬
LTD.,
,‫ פארק לתעשיות עתירות ידע‬,‫קרית ויצמן‬
NES ZIONA 76110
‫ציונה‬-‫נס‬
]71[
]15[
[57] A glucocorticoid-induced leucinezipper family related (GILR) protein
capable of inhibiting apoptosis and
February 11, 2007 – ‫כ"ג בשבט התשס"ז‬
stimulating lymphocyte activity, wherein
said GILR protein:
(a) is encoded by the nucleotide sequence
of SEQ ID NO: 1; or
(b) contains no more than five amino acid
changes from the amino acid sequence of
SEQ ID NO: 2, each of said changes being
either alternative conservative substitutions
within one of the following five groups of
amino acid residues:
4368
(1) Ala, Ser, Thr, Pro, Gly;
(2) Asp, Asn, Glu, Gln;
(3) His, Arg, Lys;
(4) Met, Leu, Ile, Val, Cys; and
(5) Phe, Tyr, Trp
or deletion of one or more of residues 123,
124, and 125 of SEQ ID NO:2.
__________
]22[]12[
716000
,‫מצמד תריתארפין סאפונין–ליפופילי‬
‫תכשיר רוקחות המכיל אותו וחיסון המכיל‬
‫אותו‬
]45[
TRITERPENE SAPONINLIPOPHILE CONJUGATE, A
PHARMACEUTICAL
COMPOSITION CONTAINING
THE SAME AND A VACCINE
CONTAINING THE SAME
]11[
]32[
20.05.1998
60/047129
]31[ 20.05.1997
]33[ US
213171370
1121522007
US
Int. Cl.8 A61K 031/704, 039/00, A61P 037/00, C07H 015/256
GALENICA PHARMACEUTICALS,
INC., U.S.A.
WO/1998/052573
WOLFF, BREGMAN AND GOLLER,
,‫ ברגמן וגולר‬,‫וולף‬
19B KEREN HAYESOD ST.
‫ ירושלים‬,6076 .‫ד‬.‫ ת‬, '‫ב‬67 ‫רחוב קרן היסוד‬
P.O.B. 1352,
JERUSALEM 91013
]42[
]12[
]71[
]15[
[57] A triterpene saponin-lipophile
conjugate, comprising a nonacylated or
desacylated triterpene saponin that
includes a 3-glucuronic acid residue; and a
lipophilic moiety; wherein said saponin
and said lipophilic moiety are covalently
attached to one another, either directly or
through a linker group, and wherein said
direct attachment or attachment to said
linker occurs through a covalent bond
between the carboxyl carbon of said 3glucuronic acid residue, and a suitable
functional group on the liphophilic residue
or linker group.
__________
]22[]12[
]45[
4369
DERIVATIVES OF
ERYTHROMYCIN, THEIR
711767
‫ תהליך הכנתן‬,‫תולדות אריתרומיצין‬
‫ותכשירי רוקחות המכילים אותן‬
PREPARATION PROCESS AND
PHARMACEUTICAL
COMPOSITIONS CONTAINING
THEM
]11[
]32[
]42[
]12[
]11[
]15[
23.11.1999
98/14782
]31[ 24.11.1998
]33[ FR
Int. Cl.8 A61K 031/7056, A61P 031/00, C07D 231/12, 401/06, C07H 017/08, C12P
019/62
AVENTIS PHARMA S.A., FRANCE
ALEXIS DENIS
PEARL COHEN ZEDEK LATZER,
‫ עורכי פטנטים‬,‫פרל כהן צדק לצר עורכי דין‬
5 SHENKAR STREET,
,‫ונוטריונים‬
P.O.BOX 12704
,66930 .‫ד‬.‫ ת‬, 7‫ רח' שנקר‬,6 ‫ים‬-‫מרכז גב‬
HERZLIYA 46733
‫הרצליה‬
[57] Compounds of the formula
and their addition salts with acids:
in which
Y represents a hydrogen atom or a fluorine
atom,
n represents an integer between 1 and 8,
Z represents a hydrogen atom or the
remainder of a carboxylic acid, substituted
on the pyrazole by one or more aryl
radicals containing up to 14 carbon atoms
or heteroaryl radicals containing one or
more nitrogen, oxygen or sulphur atoms,
the aryl or heteroaryl radicals themselves
being able to be substituted by one or more
alkyl, alkenyl, alkynyl O-alkyl, O-alkenyl,
O-alkynyl, S-alkyl, S-alkenyl, S-alkynyl
containing up to 8 carbon atoms or by one
or more OH, NH2, C≡N, NO2, CF3
radicals.
__________
]22[]12[
]45[
GENERATING INORGANIC
POLYMER ELECTRET IN
COLLOIDAL STATE
February 11, 2007 – ‫כ"ג בשבט התשס"ז‬
711171
‫יצירה של אלקטרט פולמרי אנאורגני‬
‫במצב קולואידי‬
4370
]11[
]32[
]42[
]12[
]71[
]15[
05.06.1998
60/048766
]31[ 05.06.1997
213121121
1722122001
213120124
2122122001
213174170
2321422007
Int. Cl.8 B01J 013/00, C01B 033/151
ROBERT R HOLCOMB, U.S.A.
WO/1998/055219
DR. MARK FRIEDMAN LTD.,
BEIT SAMUELOFF, 7 HAOMANIM
STREET
TEL AVIV
[57] An inorganic silicate polymer
electret in a colloidal state with a zeta
potential between about 33 and 50 mV,
said inorganic polymer electret in a
colloidal state being formed by prolonged
flow through a counter current device, said
flow generating a charge effect, which
]33[
US
US
US
US
,‫ד"ר מרק פרידמן ושות‬
‫ תל אביב‬,9 ‫בית שמואלוב רח' האומנים‬
generates multiple bi-directional magnetic
fields and an electrostatic charge on the
adjacent moving charged colloid particles
moving in the counter current flow,
resulting in the inorganic silicate polymer
electret in a colloidal state.
__________
]22[]12[
]45[
STEERING SYSTEM AND
METHOD
]11[
]42[
]12[
24.01.2000
Int. Cl.8 F42B 010/64
ISRAEL AIRCRAFT INDUSTRIES
LIMITED
BOROCHOV, KORAKH, ELIEZRI &
CO,
15 TH FLOOR, ATIDIM TOWER,
KIRYAT ATIDIM
P.O.BOX 58100
TEL AVIV 61580
]15[
717700
‫התקן ושיטה לניווט‬
‫ לוד‬,‫התעשיה האווירית לישראל בע"מ‬
,'‫בורוכוב קורח אליעזרי ושות‬
‫אביב‬-‫ תל‬,71633 .‫ד‬.‫ ת‬, ‫מגדל כלל עתידים‬
[57] Apparatus for controlling a flight
path of a flying object, the object including
at least one static fin (302B), the apparatus
comprising: a housing (300); and at least
two dynamic fins (302A, 302C) rotatably
connected to said housing, wherein said at
least one static fin and said at least two
dynamic fins intersect a plane, said plane
4371
being normal to a longitudinal axis of said
flying object.
__________
]22[]12[
717716
‫השימוש בהרכבים המכילים סיטידין‬
‫וסיטוסין להכנת תכשיר תרופתי עבור‬
‫טיפולים נגד לחומרים ממריצים‬
]45[
USE OF CYTIDINE-CONTAINING
AND CYTOSINE-CONTAINING
COMPOUNDS IN THE
PREPARATION OF A
MEDICAMENT FOR THE
TREATMENT OF STIMULANT
EXPOSURE
]11[
]32[
]42[
]12[
05.08.1998
08/908997
]31[ 08.08.1997
]33[ US
Int. Cl.8 A61K 031/513, 031/7068, A61P 025/30, C07D 239/47, C07H 019/067
THE MCLEAN HOSPITAL
CORPORATION, U.S.A.
WO/1999/007385
SELIGSOHN GABRIELI & CO.,
,'‫זליגסון גבריאלי ושות‬
31 YAVNE ST.
‫ תל אביב‬,6062 .‫ד‬.‫ ת‬, 06 ‫רח' יבנה‬
P.O.B. 1426
TEL AVIV 61013
]71[
]15[
[57] Use of a compound containing
cytidine or cytosine in the preparation of a
medicament for the treatment of mammals
exposed to a stimulant, when administered
in a therapeutically-effective amount.
__________
]22[]12[
]45[
FASTENER ASSEMBLY
February 11, 2007 – ‫כ"ג בשבט התשס"ז‬
718107
‫מכלול מחבר‬
4372
]11[
]42[
]12[
]15[
30.03.2000
Int. Cl.8 F16B 005/00, 013/00, 023/00
MOSHE LAVI
EITAN, PEARL, LATZER AND
COHEN ZEDEK,
P.O.B. 12688,
HERZLIYA 46733
[57] A through-wall fastener assembly
(10) for secure attachment of a load
carrying platform (12) to the outer face
(22) of a wall (24), said assembly
comprising a tension rod member (16)
longer than the thickness of said wall
having a rigidly attached non-cylindrical
stop member (32) at a proximate end (34),
a removable dished washer (14) being
‫ גבעתיים‬,‫משה לביא‬
,‫ לצר וכהן צדק‬,‫ פרל‬,‫איתן‬
‫ הרצליה‬,66211 .‫ד‬.‫ ת‬, 9 ‫רחוב שנקר‬
positionable to abut and envelope said stop
member, said dished washer being
configured to distribute a force to an inner
face of said wall, said tension rod member
being provided with a screw thread (26)
and nut (28) at a distal end (30) for holding
a member of said platform to said outer
face of said wall.
__________
]22[]12[
4373
718861
]45[
ENDOSCOPE WITH SINGLE-USE
CARTRIDGE FOR THE
INVAGINATION OF
ENDOSCOPIC TUBE
]11[
]32[
02.10.1998
P-97-190
]31[ 03.10.1997
P-98-188
1321022007
Int. Cl.8 A61B 001/00
SERGEY MATASOV
WO/1999/017655
M. GROSSMAN,
P.O.B 1174
KIRIAT HAIM
]42[
]12[
]71[
]15[
[57] An endoscope with disposable
cartridges for the invagination of
endoscopic tube, comprising: an
endoscopic tube (3) having a distal part
with a guided distal end;
a disposable cartridge located on the distal
part of the endoscopic tube and comprising
an invaginator of the endoscopic tube,
‫אנדוסקופ עם תרמיל חד–פעמי עבור‬
‫אינווגינציה של צינור אנדוסקופי‬
]33[
LV
LV
‫ קירית חיים‬,
,‫ גרוסמן‬.‫מ‬
‫ קרית חיים‬,6690 .‫ד‬.‫ ת‬,
which invaginator is an eversible tube with
an uneverted end (7) joined with the
endoscopic tube, and an uneverted part of
invaginator formed by pleats into a
compact hollow cylinder (23), having a
gap (25) with the distal part of the
endoscopic tube.
__________
]22[]12[
February 11, 2007 – ‫כ"ג בשבט התשס"ז‬
710616
4374
]45[
PHARMACEUTICAL COMPOSITIONS
CONTAINING RACEMIC MIXTURES
OF PROPYLISOPROPYLACETIC
ACID AND
PROPYLISOPROPYLACETAMIDE
FOR THE TREATMENT OF
NEUROLOGICAL, PSYCHOTIC AND
PSYCHIATRIC DISORDERS AND
PAIN
]11[
]42[
]21[
]12[
16.04.1998
Int. Cl.8 C07C 053/126
DIVISION FROM 124118
YISSUM RESEARCH DEVELOPMENT
COMPANY OF THE HEBREW
UNIVERSITY OF JERUSALEM
]15[
REINHOLD COHN AND PARTNERS,
21 AHAD HAAM STREET
P.O.B. 4060
TEL AVIV 61040
‫תכשירים רוקחיים המכילים תערובות‬
‫רצמיות של חומצה‬
‫פרופיאזופרופילאצטטית ושל‬
‫ לטיפול‬,‫פרופילאיזופרופילאצטאמיד‬
,‫ פסיכוטיות‬,‫במחלות נירולוגיות‬
‫פסיכיאטריות ולטיפול בכאבים‬
‫יישום חברה לפיתוח המחקר של‬
,‫האוניברסיטה העברית בירושלים‬
‫ירושלים‬
,‫ריינהולד כהן ושותפיו‬
-‫ תל‬,0323 .‫ד‬.‫ ת‬, 66 ‫רחוב אחד העם‬
‫אביב‬
[57] Racemic propylisopropyl acetic acid
and propylisopropyl acetamide and their
isomers in their racemic forms, for use in
treatment of neurological, psychotic and
psychiatric disorders, excluding convulsant
and epileptic disorders, and to treat pain,
headaches and migraine, wherein the
isomers are of the compound the formula
wherein R1 is a methyl or ethyl group;
R2 is H, methyl or an ethyl group;
R3 is ethyl or a propyl group; and
R4 is a hydroxyl or amide group,
wherein the total number of carbon atoms
in said compound is 8, provided that when
R1 is a methyl group and R4 is an amide
group, R2 and R3 are not ethyl, further
provided that the compound valpromide
(R1=ethyl, R2=H, R3=propyl, R4=NH2),
valproic acid (R1=ethyl, R2=H, R3=propyl,
R4=OH), di-isopropylacetic acid
(R1=methyl, R2=methyl, R3=isopropyl,
R4=OH), valnoctamide (R1=ethyl,
R2=methyl, R3=ethyl, R4=NH2), and
valnoctic acid (R1=ethyl, R2=methyl,
R3=ethyl, R4=OH), are excluded.
The parent application from which this
application has been divided has not yet
been published
817881
‫בקשת הורה לבקשה זו שטרם‬
‫פורסמה‬
__________
]22[]12[
]45[
4375
METHODS FOR SEPARATING A
710088
‫שיטה להפרדה של מולקולה ממולקולות‬
MOLECULE FROM OTHER
MOLECULES OF A SIMILAR
HYDRODYNAMIC VOLUME
THERETO BY CHANGING ITS
HYDRODYNAMIC VOLUME BY
INTERACTION THEREOF WITH
AT LEAST ONE LIGAND
]11[
]32[
]42[
]12[
]71[
]15[
‫אחרות בעלות נפח הידרו–דינמי דומה‬
‫לשלה על ידי אינטרקציה שלה עם לפחות‬
–‫ליגנד אחד בכדי לשנות את הנפח ההידרו‬
‫דינאמי שלה‬
10.12.1998
08/998413
]31[ 24.12.1997
]33[ US
Int. Cl.8 C07K 001/16, 001/20, 001/22, 001/32
GENENTECH, INC., U.S.A.
WO/1999/033862
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל אביב‬,0323 .‫ד‬.‫ ת‬, 66 ‫רחוב אחד העם‬
P.O.BOX 4060,
TEL AVIV 61040
[57] A method for separating a first
species of interest from a second species of
interest in a free solution mixture
comprising said first and second species of
interest, said first and second species
having about the same hydrodynamic
volume, said method comprising:
contacting said free solution mixture with
one or more ligands soluble in said free
solution mixture, where said one or more
ligands interacts with said first species,
wherein the molecular weight of said one
or more ligands is smaller than the
molecular weight of said first species and
wherein said interaction forms a first
species/ligand complex which has a larger
hydrodynamic volume than said second
species in free solution; and separating
said first species/ligand complex from said
second species by size exclusion
chromatography or membrane filtration;
providing a composition which is
essentially free of said second species; and
wherein said first species is selected from
the group consisting of a protein and a
polypeptide.
__________
]22[]12[
]45[
MULTIPOINT DIGITAL
SUBSCRIBER LINES WITH
February 11, 2007 – ‫כ"ג בשבט התשס"ז‬
710106
‫נקודותיים למנויים עם‬-‫קווי תקשורת רב‬
‫יכולת תקשורת ביתית‬
4376
HOME DATA NETWORK
ABILITY
]11[
]32[
]42[
]12[
]15[
15.06.2000
134402
]31[ 06.02.2000
Int. Cl.8 H04M 011/06
COPPERGATE COMMUNICATION
LTD.
ALPHAPATENT LTD.,,
55 REUVEN STREET
BET-SHEMESH 99544
[57] A network DSL (NDSL) modem for
communicating on an xDSL telephone
line, the NDSL modem comprising: a
network modem to communicate along an
upstream frequency band of said xDSL
line with at least one other NDSL modem
connected in a subscriber premises to said
]33[
IL
‫ תל אביב‬,‫קופרגייט תקשורת בע"מ‬
,‫אלפאפטנט עמיתים בע"מ עו"פ‬
‫ בית שמש‬,77 ‫רח' ראובן‬
xDSL telephone line; and a control tone
transmitter to transmit a control signal to
which a central office modem in a central
office (CO) of a communication system is
not receptive for signaling said at least one
other NDSL modem to be ready to receive
data packets.
__________
]22[]12[
]45[
4377
MONITORING AND CONTROL
FOR A LARYNGEAL MASK
AIRWAY DEVICE
710000
‫בקרה וינטור למסכה עם צינור למעבר אויר‬
‫לקנה הנשימה‬
]11[
]32[
]42[
]12[
]71[
]15[
21.12.1998
9727367.6
]31[ 24.12.1997
Int. Cl.8 A61M 016/04
INDIAN OCEAN MEDICAL INC.,
SEYCHELLES
WO/1999/033508
LUZZATTO & LUZZATTO,
INDUSTRIAL PARK, OMER
P.O.B 5352
BEER-SHEVA 84152
[57] Apparatus (10) for monitoring the
level of unconsciouseness of a patient in
the course of a surgical procedure on the
patient, wherein the patient has an installed
inflatable device (19) having wall contact
with at least a portion of the patient's
pharynx, characterised in that said
apparatus comprises:
(a) syringe means (26) having a piston (27)
displaceable in an elongate cylinder with
an outlet connection (11b) connectable to
said inflatable device for supply of
inflation/deflation air;
(b) reversibly operable drive means (34)
for reversibly displacing said piston and
cylinder with respect to each other
whereby to be able to selectively displace
air to or from said inflatable means;
(c) control means including:
February 11, 2007 – ‫כ"ג בשבט התשס"ז‬
]33[
GB
,‫לוצאטו את לוצאטו‬
‫ באר שבע‬,7076 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
(i) pressure-responsive means (P1, P2)
connected for response to instantaneous
pressure at said outlet connection,
(ii) adjustable means (56) for selecting a
set-point value of inflation pressure, and
(iii) comparator means (40, 58, 59)
connected for response to said set-point
value and to said pressure-responsive
means for providing an output (60)
representative of the polarity of an
evaluated difference between
instantaneous pressure and the selected setpoint value; and
(d) means (47) connecting said output (60)
for operation of said drive means to
displace said piston and cylinder with
respect to each other in the direction to
reduce to zero the output provided by said
comparator means.
4378
__________
]22[]12[
711770
‫תולדות חומצות הידרוקסמית‬
‫וקרבוקסילית‬
]45[
HYDROXAMIC AND
CARBOXYLIC ACID
DERIVATIVES
]11[
]32[
29.01.1999
9802073.8
]31[ 30.01.1998
]33[ GB
072041522
1721022007
GB
Int. Cl.8 A61K 031/16, 031/395, A61P 009/00, 019/00, C07C 317/26, 323/40, C07D
205/04, 207/10, 209/30, 211/54, 213/70, 215/36, 295/18, 307/18
DARWIN DISCOVERY LIMITED,
UNITED KINGDOM
WO/1999/038843
DR. YITZHAK HESS & PARTNERS,
,‫ עו"פ‬,‫ד"ר יצחק הס ושותפיו‬
279 HAYARKON STREET
‫ תל אביב‬,2076 .‫ד‬.‫ ת‬, 697 ‫רחוב הירקון‬
P.O.B. 6451
TEL AVIV 61063
]42[
]12[
]71[
]15[
4379
[57] Compounds of the formula
B-X-(CH2)m-(CR1R2)n-N(OR8)-COH
wherein
m = 0-2;
n = 1-2, provided that when m = 0 then n
=2;
X is S(O)0-2;
R1 is H or a group (optionally substituted
with R7) selected from C1-6 alkyl, C2-6
alkenyl, aryl, C1-6 alkyl-aryl, heteroaryl,
C1-6 alkyl-heteroaryl, heterocycloalkyl, C16 alkyl-heterocycloalkyl, cycloalkyl and
C1-6 alkyl-cycloalkyl; and
R2 is H or C1-6 alkyl, provided that
(CR1R2)n is not (CH2)n;
or CR1R2 is a cycloalkyl or
heterocycloalkyl ring optionally
substituted with R7 or a group (optionally
substituted with R7) selected from C1-6
alkyl, aryl, C1-6 alkyl-aryl, heteroaryl and
C1-6 alkyl-heteroaryl;
B is C1-6 alkyl-aryl, C1-6 alkyl, cycloalkyl,
C1-6 alkyl-cycloalkyl, cycloalkenyl,
heterocycloalkenyl, C1-6 alkyl-heteroaryl,
heterocycloalkyl, C1-6 alkylheterocycloalkyl or heteroaryl, any of
which groups is optionally substituted by a
substituent selected from R3, C1-6 alkyl-R3,
C2-6 alkenyl-R3, aryl (optionally substituted
with R3), aryl- C1-6 alkyl-R3, C1-6 alkyl-aryl
(optionally substituted with R3), C1-6 alkylheteroaryl (optionally substituted with R3),
aryl-C2-6 alkenyl-R5, heteroaryl (optionally
substituted with R3), heteroaryl- C1-6 alkylR3, cycloalkyl (optionally substituted with
R3), or heterocycloalkyl (optionally
substituted with R3); R3 is C1-6 alkyl,
halogen, CN, NO2, N(R4)2, OR4, COR4,
C(=NOR6)R4, CO2R5, CON(R4)2, NR4R5,
S(O)0-2R6 or SO2N(R4)2;
R4 is H or a group selected from C1-6 alkyl,
aryl, C1-6 alkyl-aryl, heteroaryl, C1-6 alkylheteroaryl, cycloalkyl, C1-6 alkylcycloalkyl, heterocycloalkyl and C1-6 alkylheterocycloalkyl, wherein said group is
optionally optionally substituted with R6,
COR6, SO0-2R6, CO2R6, OR6, CONR8R6,
NR8R6, halogen, CN, SO2NR8R6, NR8R6,
halogen, CN, SO2NR8R6 or NO2, and for
each case of N(R4)2 is heterocycloalkyl
optionally substituted with R6, COR6, SO06
6
6
8 6
8 6
2R , CO2R , OR , CONR R , NR R ,
8 6
halogen, CN, SO2NR R or NO2;
R5 is COR4, CON(R4)2, CO2R6 or SO2R6;
R6 is C1-6 alkyl, aryl, C1-6 alkyl-aryl,
heteroaryl, or C1-6 alkyl-heteroaryl; R7 is
OR4, COR4, CO2R8, CON(R4)2, NR4R5,
S(O)0-2R6, SO2N(R4)2, halogen, CN or
cycloimidyl (optionally substituted with
R8); and R8 is H or C1-6 alkyl; wherein
cycloalkyl or heterocycloalkyl is
optionally benzofused at any available
position; wherein any amino group is
optionally protected by a
benzyloxycarbonyl, tert-butoxycarbonyl,
or acetyl group, or is in the form of a
phthalimido group; or a salt, hydrate or Noxide thereof.
__________
February 11, 2007 – ‫כ"ג בשבט התשס"ז‬
4380
]22[]12[
‫התקן מסד נתונים‬
]45[
DATABASE APPARATUS
]11[
]32[
]42[
]12[
22.01.1999
PCT/IL98/00029 ]31[ 22.01.1998
Int. Cl.8 G06F 017/30
ORI SOFTWARE DEVELOPMENT
LTD.
WO/1999/038094
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.BOX 4060,
TEL AVIV 61040
]71[
]15[
711171
[57] In a database file management
system for accessing data records and
being executed on data processing system;
the data records are associated with a basic
partitioned index arranged in blocks and
being stored in a storage medium; the basic
partitioned index enables accessing or
updating the data records by key or keys
and being susceptible to an unbalanced
structure of blocks; a method for
constructing a layered index I0,…,Ih
]33[
‫אורי פיתוח תוכנה בע"מ‬
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,0323 .‫ד‬.‫ ת‬, 66 ‫רחוב אחד העם‬
arranged in blocks, comprising the steps
of:
(a) providing said basic partitioned index
I 0;
(b) constructing a representative index
over representative keys of said basic
partitioned index; said layered index
enables accessing or updating the data
records by key or keys and constitutes an
essentially balanced structure of blocks.
__________
4381
WO
]22[]12[
]45[
METHOD FOR THE
PRODUCTION OF TRANSGENIC
PLANTS USING APICAL SHOOT
TIPS
]11[
]32[
]42[
]12[
]71[
]15[
18.02.1999
60/075261
]31[ 19.02.1998
Int. Cl.8 A01H 004/00, C12N 015/87
COTTON INCORPORATED, U.S.A.
WO/1999/041975
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.BOX 4060,
TEL AVIV 61040
[57] A method for producing a
transformed plant comprising,
(a) isolating apical shoot tips from threeday-old seedlings;
(b) chilling the isolated apical shoot tips
for a sufficient period of time to slow the
metabolic activity of cells and to
acuumulate the cells at a single stage of
cell division or mitosis;
711776
‫שיטה לייצור צמחים טרנסגניים באמצעות‬
‫קצה נצר חודי‬
]33[
US
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,0323 .‫ד‬.‫ ת‬, 66 ‫רחוב אחד העם‬
(c) dissecting the apical shoot tips to
expose meristematic cells;
(d) introducing a transforming agent into
the dissected apical shoot tips, wherein
said transforming agent is a DNA
molecule comprising a gene conferring a
desired phenotypic trait to the plant; and
(e) regenerating a transgenic plant from
shoots which form on the meristematic
cells.
__________
]22[]12[
]45[
SUBSTRATE FOR PACKAGING
PERISHABLE GOODS
CONTAINING A REVERSIBLE
INDICATOR
]11[
]32[
]42[
]12[
27.01.1999
19803208.0
]31[ 28.01.1998
Int. Cl.8 G01N 031/22
YOAV EICHEN
DIETRICH HAARER, GERMANY
]71[
]15[
WO/1999/039197
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.BOX 4060,
February 11, 2007 – ‫כ"ג בשבט התשס"ז‬
711716
‫מצג לאריזת מוצרים הנתנים לקלקול‬
‫הכולל מחון הפיך‬
]33[
DE
‫ חיפה‬,‫יואב איישן‬
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,0323 .‫ד‬.‫ ת‬, 66 ‫רחוב אחד העם‬
4382
TEL AVIV 61040
[57] Substrate for packaging of or for
attachment to products which are sensitive
to aging and temperature, having a timetemperature integrator arranged in the
region of the substrate, wherein the timetemperature integrator contains a matrix
and at least one reversible, crystalline
indicator embedded therein, which has
photochromic properties on the basis of
transfer reactions in crystalline materials,
and wherein further the reversible indicator
is characterized by discoloration following
photo-induced coloration thereof, the
discoloration of the reversible indicator
proceeding as a function of both time and
temperature.
__________
]22[]12[
]45[
]11[
]32[
]42[
]12[
]71[
]15[
INTEGRATED ADDITIVE
COMPOSITION CONTAINING
ANTI-BLOCKING AGENTS,
PROCESS FOR ITS
PREPARATION AND ITS USE
03.02.1999
19805358.4
]31[ 12.02.1998
Int. Cl.8 C08K 009/00, 013/02
GRACE GMBH & CO. KG,
GERMANY
WO/1999/041308
SANFORD T.COLB & CO.,
P.O.B. 2273,
REHOVOT
[57] Integrated additive composition
which contains anti-blocking agents and at
least one organic component, characterized
in that the organic component(s) is (are)
localized in a concentration of 5 to 65 wt.%, relative to the total weight of the
composition, in the pores of the antiblocking agent, the volume of the organic
component(s) not being greater, however,
than the pore volume of the anti-blocking
agent, and the organic additive component
comprises, in any proportions, one or more
of the following components selected from
the group consisting of slip agents from the
group of fatty acid amides, primary
antioxidants from the group of phosphorus
compounds, thioesters and
hydroxylamines, secondary anti-oxidants
4383
711100
‫תכשיר תוסף משולב המכיל גורמים נוגדי‬
‫ תהליך להכנתו ושימושיו‬,‫הדבקה‬
]33[
DE
,,'‫ קולב ושות‬.‫סנפורד ט‬
‫ רחובות‬,6690 .‫ד‬.‫ ת‬, ‫ מרמורק‬,0 ‫שער הגיא‬
from the group of ammonium salts,
glycerol esters and anion-active
substances, light stabilizers from the group
of benzophenones, benzotriazoles and
HALS (sterically hindered amine light
stabilizers), flame-protection agents and
synergistic substances from the group of
halogenated organic molecules and metal
hydrates, plasticizers from the group of
phthalates, process auxiliaries from
glycerol and/or the group of alcohol esters,
wax amides, fatty acids, metal stearates,
natural waxes and polyethylene and
polypropylene waxes and other additives
from the group of antimicrobial agents,
propellants, organic peroxides, fillers and
stabilizers.
__________
]22[]12[
710771
‫ חומרים ביניים‬,‫סינטתזת אפותילונים‬
‫וחומרים מקבילים להם‬
]45[
SYNTHESIS OF EPOTHILONES,
INTERMEDIATES THERETO AND
ANALOGUES THEREOF
]11[
]32[
24.02.1999
60/075947
]31[ 25.02.1998
]33[ US
213101320
1021122007
US
213101133
1521722007
US
Int. Cl.8 C07C 059/76, 069/66, C07D 209/00, 213/00, 313/00, 405/00, 407/00,
413/00, 417/00, C07F 007/02
SLOAN-KETTERING INSTITUTE
FOR CANCER RESEARCH, U.S.A.
WO/1999/043653
SELIGSOHN GABRIELI & CO.,
,'‫זליגסון גבריאלי ושות‬
31 YAVNE ST.
‫ תל אביב‬,6062 .‫ד‬.‫ ת‬, 06 ‫רח' יבנה‬
P.O.B. 1426
TEL AVIV 61013
]42[
]12[
]71[
]15[
[57] A method of preparing a
desoxyepothilone having the structure:
wherein R, R0, and R' are independently H,
linear or branched chain alkyl, optionally
substituted by hydroxy, alkoxy, carboxy,
carboxaldehyde, linear or branched alkyl
or cyclic acetal, fluorine, NR1R2, Nhydroximino, or N-alkoxyimino, wherein
R1 and R2 are independently H, phenyl,
benzyl, linear or branched chain alkyl;
wherein R" is –CY=CX-, or H, linear or
branched chain alkyl, phenyl, 2-methyl1,3-thiazolinyl, 2-furanyl, 4-furanyl, 2pyridyl, 3-pyridyl, 4-pyridyl, imidazolyl,
2-methyl-1,3-oxazolinyl, 3-indolyl or 6February 11, 2007 – ‫כ"ג בשבט התשס"ז‬
indolyl; wherein X is H, linear or branched
chain alkyl, phenyl, 2-methyl-1,3thiazolinyl, 2-furanyl, 3-furanyl, 4-furanyl,
2-pyridyl, 3-pyridyl, 4-pyridyl, imidazolyl,
2-methyl-1,3-oxazolinyl, 3-indolyl or 6indolyl; wherein Y is H or linear or
branched chain alkyl; wherein Z is O,
N(OR3) or –N-NR4R5, wherein R3, R4 and
R5 are independently H or a linear or
branched alkyl; and wherein n is 0, 1, 2, or
3; which comprises treating an epothilone
having a structure:
4384
wherein R, Ro, R1, R2, R3, R4, R5, R', R",
X, Y, Z and n are defined as for the
desoxyepothilone, under suitable
conditions so as to deoxygenate the
epothilone, and thereby to provide the
desoxyepothilone.
A method of preparing a hydroxy acid
desoxyepothilone precursor having the
structure:
wherein R, Ro, and R' are independently H,
linear or branched chain alkyl, optionally
substituted by hydroxy, alkoxy, carboxy,
carboxaldehyde, linear or branched alkyl
or cyclic acetal, fluorine, NR1R2, Nhydroximino, or N-alkoxyimino, wherein
R1 and R2 are independently H, phenyl,
benzyl, linear or branched chain alkyl;
wherein R" is –CY=CHX, or H, linear or
branched chain alkyl, phenyl, 2-methyl1,3-thiazolinyl, 2-furanyl, 3-furanyl, 4furanyl, 2-pyridyl, 3-pyridyl, 4-pyridyl,
imidazolyl, 2-methyl-1,3-oxazolinyl, 3indolyl or 6-indolyl; wherein X is H, linear
or branched chain alkyl, phenyl, 2-methyl1, 3-thiazolinyl, 2-furanyl, 3-furanyl, 4furanyl, 2-pyridyl, 3-pyridyl, 4-pyridyl,
imidazolyl, 2-methyl-1,3-oxazolinyl, 3indolyl or 6-indolyl; wherein Y is H or
linear or branched chain alkyl; wherein n is
2 or 3; wherein RA is a linear or branched
alkyl, alkoxyalkyl, substituted or
unsubstituted aryloxyalkyl, trialkylsilyl,
aryldialkylsilyl, diarylalkylsilyl,
triarylsilyl, linear or branched acyl,
substituted or unsubstituted aroyl or
benzoyl; wherein RB is hydrogen, tbutyloxycarbonyl, amyloxycarbonyl,
(trialkylsilyl) alkyloxycarbonyl,
(dialkylarylsilyl) alkyloxycarbonyl,
benzyl, trialkylsilyl, dialkylarylsilyl,
alkyldiarylsilyl, triarysilyl, linear or
branched acyl, substituted or unsubstituted
aroyl or benzoyl; which comprises
selectively etherifying and hydrolyzing a
hydroxy ester desoxyepothilone precursor
having the structure:
4385
wherein R, Ro, RB, RC, R', R" and n are
defined as above; and wherein RC is
tertiary-alkyl; under suitable conditions to
form the hydroxy acid desoxyepothilone
precursor.
A method of preparing a hydroxy ketoester
desoxyepothilone precursor having the
structure:
wherein P is H; wherein R, Ro, and R' are
independently H, linear or branched chain
alkyl, optionally substituted by hydroxy,
alkoxy, carboxy, carboxaldehyde, linear or
branched alkyl or cyclic acetal, fluorine,
NR1R2, N-hydroximino, or Nalkoxyimino, wherein R1 and R2 are
independently H, phenyl, benzyl, linear or
branched chain alkyl; wherein R" is –
CY=CHX, or H, linear or branched chain
alkyl, phenyl, 2-methyl-1,3-thiazolinyl, 2furanyl, 3-furanyl, 4-furanyl, 2-pyridyl, 3pyridyl, 4-pyridyl, imidazolyl, 2-methyl1,3-oxazolinyl, 3-indolyl or 6-indolyl;
wherein X is H, linear or branched chain
alkyl, phenyl, 2-methyl-1, 3-thiazolinyl, 2-
furanyl, 3-furanyl, 4-furanyl, 2-pyridyl, 3pyridyl, 4-pyridyl, imidazolyl, 2-methyl1,3-oxazolinyl, 3-indolyl or 6-indolyl;
wherein Y is H or linear or branched chain
alkyl; wherein n is 2 or 3; wherein RB is
hydrogen, t-butyloxycarbonyl,
amyloxycarbonyl, (trialkylsilyl)
alkyloxycarbonyl, (dialkylarylsilyl)
alkyloxycarbonyl, benzyl, trialkylsilyl,
dialkylarylsilyl, alkyldiarylsilyl, triarysilyl,
a linear or branched acyl, substituted or
unsubstituted aroyl or benzoyl; and
wherein RC is tertiary-alkyl; which
comprises deprotecting a protected
ketoester desoxyepothilone precursor
having the structure:
February 11, 2007 – ‫כ"ג בשבט התשס"ז‬
4386
wherein R, Ro, RA, RB, RC, R', R" and n are
defined as above; and wherein P is a linear
or branched alkyl, alkoxyalkyl, substituted
or unsubstituted aryloxyalkyl, trialkylsilyl,
aryldialkylsilyl, diarylalkylsilyl or
triarylsilyl; under suitable conditions to
form the hydroxy ketoester
desoxyepothilone precursor. A method of
preparing metalvinyl compound having the
structure:
wherein R, P and R" are defined as above;
and wherein Q is a halide or a metal; under
suitable conditions to form the protected
ketoester desoxyepothilone precursor. A
method of preparing a terminal vinyl enol
ether ester having the structure:
wherein Ro and R' are independently H,
linear or branched chain alkyl, optionally
substituted by hydroxy, alkoxy, carboxyl,
carboxaldehyde, linear or branched alkyl
or cyclic acetal, fluorine, NR1, R2, Nhydroximino, or N-alkoxyimino, wherein
R1 and R2 are independently H, phenyl,
benzyl, linear or branched chain alkyl;
wherein m is 0, 1 or 2; wherein RB is
hydrogen, t-buyloxycarbonyl,
amyloxycarbonyl, (trialkylsilyl) alkyloxycarbonyl, (dialkylarylsilyl) alky-
loxycarbonyl, benzyl, trialkylsilyl,
dialkylarylsilyl, alkyldiarylislyl, triarysilyl,
linear or branched acyl, substituted or
unsubstituted aroyl or benzyl; wherein RC
is tertiary-alkyl; and wherein RD is linear
or branched alkyl, benzyl, trialkylsilyl,
dialkylarylsilyl, alkyldiarylsilyl, triarysilyl,
linear or branched acyl, substituted or
unsubstituted aroyl or benzoyl; which
comprises:
(a) treating a keto enol ester having the
structure:
4387
under suitable conditions to form an
enolate enol ester having the structure:
wherein M is Li, Na or K; and (b) coupling
the enolate enol ester with a vinyl aldehyde
having the structure:
wherein m, and Ro and R' are as defined
above; under suitable conditions to form
the terminal vinyl enol ether ester.
__________
]22[]12[
]45[
IDENTIFICATION DEVICE
]11[
]32[
]42[
]12[
01.03.1999
98/1719
]31[ 02.03.1998
Int. Cl.8 G06K 019/07
WAVETRAND TECHNOLOGIES
LIMITED, ISLE OF MAN (U.K)
WO/1999/045500
WOLFF, BREGMAN AND GOLLER,
19B KEREN HAYESOD ST.
P.O.B. 1352,
JERUSALEM 91013
]71[
]15[
February 11, 2007 – ‫כ"ג בשבט התשס"ז‬
710661
‫מתקן זיהוי‬
]33[
ZA
,‫ ברגמן וגולר‬,‫וולף‬
‫ ירושלים‬,6076 .‫ד‬.‫ ת‬, '‫ב‬67 ‫רחוב קרן היסוד‬
4388
[57] An electronic tag (10) which
includes a magnetically activateable switch
(18); microprocessor based circuitry (14)
including storage means (20) and at least
one data port, the data port being
connected to the switch, and transmitter
means (12) connected to the
microprocessor based circuitry and
operable selectively to transmit data
sourced from the microprocessor based
circuitry, with the microprocessor based
circuitry being characterised in that upon
selective activation of the switch it enters a
programmable mode of operation in which
the microprocessor based circuitry is
configured to receive data defined by
subsequent activation of the switch.
__________
]22[]12[
]45[
SECURITY SYSTEM
]11[
]32[
]42[
]12[
01.03.1999
98/1722
]31[ 02.03.1998
Int. Cl.8 G06K 017/00
WAVETRAND TECHNOLOGIES
LIMITED, ISLE OF MAN (U.K)
WO/1999/045498
WOLFF, BREGMAN AND GOLLER,
19B KEREN HAYESOD ST.
P.O.B. 1352,
JERUSALEM 91013
]71[
]15[
4389
710667
‫מערכת אבטחה‬
]33[
ZA
,‫ ברגמן וגולר‬,‫וולף‬
‫ ירושלים‬,6076 .‫ד‬.‫ ת‬, '‫ב‬67 ‫רחוב קרן היסוד‬
[57] A monitoring system (10) which
includes: a primary electronic tag (12)
including primary identification data and
associated with a primary bearer (14) of
the tag; a secondary electronic tag (16)
including secondary identification data and
associated with a secondary bearer (18) of
the tag, the secondary identification data
being associated with the primary
identification data characterized in that the
system includes reading apparatus (20) for
remotely reading the primary identification
data from the primary electronic tag and
remotely reading the secondary
identification data from the secondary
electronic tag, the reading apparatus
comprising: comparator means (26)
operable to compare the secondary
identification data and the primary
identification data and generate an output
signal dependent upon an outcome of the
comparison.
__________
]22[]12[
]45[
PHARMACEUTICAL
COMPOSITIONS COMPRISING
ERYTHROPOIETIN FOR
TREATMENT OF CANCER
]11[
]32[
]42[
]12[
30.03.1999
124015
]31[ 08.04.1998
Int. Cl.7 A61P 035/00, C07K 3818
YEDA RESEARCH AND
DEVELOPMENT CO. LTD.
MOR-RESEARCH APPLICATIONS
LTD.
ALPHA PELED, NECHAMA
HARAN-GHERA, MOSHE
MITTELMAN
WO/1999/052543
PAULINA BEN-AMI, BEN-AMI &
ASSOCIATES,
P.O.BOX 94
REHOVOT 76100
]11[
]71[
]15[
February 11, 2007 – ‫כ"ג בשבט התשס"ז‬
710168
‫תכשירי רוקחות המכילים אריתרופויטין‬
‫לטיפול בסרטן‬
]33[
IL
‫ רחובות‬,‫ידע חברה למחקר ופיתוח בע"מ‬
‫ קרית מטלון‬,‫יישום מחקרים בע"מ‬-‫מור‬
‫תקוה‬-‫פתח‬
‫ משה מיטלמן‬,‫גרא‬-‫ נחמה הרן‬,‫אלפא פלד‬
,'‫ בן עמי ושות‬, ‫עמי‬-‫פאולינה בן‬
‫ רחובות‬,70 .‫ד‬.‫ת‬
4390
[57] Use of erythropoietin for the
preparation of a pharmaceutical
composition for the treatment of cancer,
wherein the pharmaceutical composition is
in particular for inhibition of tumor
growth, triggering of tumor regression,
stimulation of the natural immunological
defense against cancer and/or inhibition of
cancer cell metastasis, wherein the tumor
is the non-solid malignant plasma cell
dyscrasia multiple myeloma.
__________
]22[]12[
710111
‫תכשירי רוקחות בעלי פעילות‬
‫אנטיסרטנית המכילים תולדות חומצה‬
‫ גליאוקסילית‬- 0 - ‫אינדוליל‬
]45[
ANTITUMORAL
PHARMACEUTICAL
COMPOSITIONS COMPRISING
INDOLYL - 3 - GLYOXYLIC ACID
DERIVATIVES
]11[
]32[
]42[
]12[
]71[
]15[
22.03.1999
19814838.0
]31[ 02.04.1998
]33[ DE
Int. Cl.8 A61K 031/40, A61P 035/00, C07D 209/12, 401/00, 403/00
ASTA MEDICA AG, GERMANY
WO/1999/051224
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל אביב‬,0323 .‫ד‬.‫ ת‬, 66 ‫רחוב אחד העם‬
P.O.BOX 4060,
TEL AVIV 61040
[57] N-Substituted indole-3glyoxylamides for use as antitumor agents,
of the formula
where the radicals R, R1, R2, R3, R4 and Z
have the following meaning:
R = hydrogen, (C1-C6)-alkyl, where the
alkyl group can be mono-or
polysubstituted by the phenyl ring and this
phenyl ring for its part can be mono- or
polysubstituted by halogen, (C1-C6)- alkyl,
4391
(C3-C7) – cycloalkyl, by carboxyl groups,
carboxyl groups esterified with C1-C6 –
alkanols, trifluoromethyl groups, hydroxyl
groups, methoxy groups, ethoxy groups,
benzyloxy groups and by a benzyl group
which is mono- or polysubstituted in the
phenyl moiety by (C1-C6)-alkyl groups,
halogen atoms or trifluoromethyl groups,
R is further the benzyloxycarbonyl group
(Z radical) and the tertiary-butoxycarbonyl
radical (BOC radical), furthermore the
acetyl group,
R1 is a phenyl ring, which is mono - or
polysubstituted by (C1-C6) – alkyl, (C1-C6)
– alkoxy, cyano, halogen, trifluoromethyl,
hydroxyl, benzyloxy, nitro, amino, (C1-C6)
– alkylamino, (C1-C6) –
alkoxycarbonylamino and by the carboxyl
group or by the carboxyl group esterified
with C1-C6 – alkanols, or can be a pyridine
structure of the formula
and its N-oxide, where the pyridine
structure is alternatively bonded to the ring
carbon atoms 2, 3 and 4 and can be
substituted by the substituents R5 and R6
and wherein radicals R5 and R6 can be
identical or different and have the meaning
(C1-C6)-alkyl and the meaning (C3-C7) –
cycloalkyl, (C1-C6) – alkoxy, nitro, amino,
hydroxyl, halogen and trifluromethyl and
further are the ethoxycarbonylamino in
which the alkyl group has 1-4 C atoms,
R1 can further be a 2- or 4-pyrimidinyl
heterocycle, where the 2-pyrididinyl ring
may be mono-or polysubstituted by the
methyl group, a 2-, 3-, and 4- and 8quinolyl structure substituted by (C1-C6) –
alkyl, halogen, the nitro group, the amino
group and the (C1-C6) – alkylamino
radical, a 2-, 3- and 4-quinolylmethyl
group, where the ring carbons of the
pyridylmethyl radical of the quinolyl group
and of the quinolymethyl radical can be
substituted by (C1-C6) – alkyl, (C1-C6) –
alkoxy, nitro, amino and (C1-C6) –
alkoxycarbonylamino, R1 in the case in
which R = hydrogen, the methyl or benzyl
group and the benzyloxycarbonyl radical
(Z radical), the tert-butoxycarbonyl radical
(BOC radical) and the acetyl group, can
furthermore be the following radicals:
-CH2COOH; -CH(CH3)-COOH; (CH3)2-
CH-(CH2)2-CH(COOH)-; H3C-H2C-CH
(CH3)-CH (COOH)-; HO-H2CCH(COOH)-; phenyl-CH2-CH (COOH)-;
(4-imidazolyl) –CH2-CH (COOH)-;
NH=C(NH2)-NH-(CH2)3-CH (COOH)-;
H2N-(CH2)4-CH(COOH)-; H2N-CO-CH2CH(COOH)-; HOOC-(CH2)2-CH(COOH)-;
R1, in the case in which R is hydrogen, the
Z radical, the BOC radical, the acetyl or
the benzyl group, can furthermore be the
acid radical of a natural or unnatural amino
acid as the α-glycyl, the α-sarcosyl, the αalanyl, the α-leucyl, the α-isoleucyl, the αseryl, the α-phenylalanyl, the α-histidyl,
the α-prolyl, the α-arginyl, the α-lysyl, the
α-asparagyl and the α-glutamyl radical,
where the amino groups of the respective
amino acids can be present unprotected or
can be protected where a possible
protective group of the amino function is
the benzyloxycarbonyl radical (Z radical )
and the tert-butoxycarbonyl radical (BOC
radical) as well as the acetyl group,
wherein R1 is an asparagyl and glutamyl
radical, the second, unbonded carboxyl
group is present as a free carboxyl group
or in the form of an ester with C1-C6alkanols, as methyl, ethyl or as a tert-butyl
ester or R1 is a allyamino-carbonyl-2methylprop-1-ylgroup, or R and R1 can
further form, together with the nitrogen
February 11, 2007 – ‫כ"ג בשבט התשס"ז‬
4392
atom to which they are bonded, a
piperazine ring of the formula 3 or a
homopiperazine ring, provided R1 is an
aminoalkylene group, in which
R7 is an alkyl radical, or is a phenyl ring
which can be mono- or polysubstituted by
(C1-C6)-alkyl, (C1-C6)-alkoxy, halogen, the
nitro group, the amino function and by the
(C1-C6) – alkylamino group, or R7 is a
benzhydryl group and a bis-pfluorobenzhydryl group.
R2 is hydrogen and a (C1-C6) – alkyl
group, where the alkyl group is mono-or
polysubstituted by halogen and phenyl,
which for its part may be mono – or
polysubstituted by halogen, (C1-C6) –
alkyl, (C3-C7)-cycloalkyl, carboxyl groups,
carboxyl groups esterified with (C1-C6) –
alkanols, trifluoromethyl groups, hydroxyl
groups, methoxy groups, ethoxy groups or
benzyloxy groups, wherein when R2 is a
(C1-C6) – alkyl group, this group can
further be substituted by the 2-quinolyl
group and the 2-, 3- and 4-pyridyl
structure, which can both in each case be
mono-or polysubstituted by halogen, (C1C4) – alkyl group or (C1-C4) – alkoxy
groups, R2 is further the aroyl radical,
where the aryl moiety on which this radical
is based is the phenyl ring, which can be
mono-or polysubstituted by halogen, (C1C6)-alkyl, (C3-C7) – cycloalkyl, carboxyl
groups esterified with C1-C6-alkanols,
trifluoromethyl groups, hydroxyl groups,
methoxy groups, ethoxy groups or
benzyloxy groups, R3 and R4 can be
identical or different and are hydrogen,
(C1-C6)-alkyl, (C3-C7)-cycloalkyl, (C1-C6)alkanoyl, (C1-C6)-alkoxy, halogen and
benzyloxy, or R3 and R4 can furthermore
be the nitro group, the amino group, the
(C1-C4)-mono or dialkyl-substituted amino
group, and the (C1-C6)alkoxycarbonylamino function or (C1-C6)alkoxycarbonylamino-(C1-C6)-alkyl
function, and Z is O and S.
__________
4393
]22[]12[
]45[
SECURE AND LINEAR PUBLICKEY CRYPTOSYSTEM BASED
ON PARITY-CHECK ERROR
CORRECTING CODE
]11[
]42[
]12[
22.10.2000
Int. Cl.8 H04L 009/30
BAR-ILAN UNIVERSITY
ERAN KANTER
]11[
]15[
IDO KANTER, ERAN KANTER
LUZZATTO & LUZZATTO,
INDUSTRIAL PARK, OMER
P.O.B 5352
BEER-SHEVA 84152
[57] A method for a secure public key
cryptography employing a parity check
error-correcting code, and noise signals,
comprising:
(a) creating a communication channel;
(b) providing a set of private cryptographic
keys which are assigned to each of the
entities utilizing said secure public
cryptography, wherein each of said private
cryptographic keys may be accessed only
by the entity it was assigned to;
711700
‫מערכת מפתח–ציבורי להצפנה מוגנת‬
‫ולינארית המבוססת על קודי תיקון שגיאה‬
‫ רמת גן‬,‫אוניברסיטת בר אילן‬
‫ערן קנטר‬
‫ ערן קנטר‬,‫עידו קנטר‬
,‫לוצאטו את לוצאטו‬
‫ באר שבע‬,7076 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
(c) providing a set of public cryptographic
keys assigned to entities untilizing said
secure public-key cryptography; and
(d) providing a set of random private noise
signals, or generating the same using a
random private noise signal generator;
the method further comprising ciphering
vectors of information by adding a noise
signal to the information vector before
encryption and/or after the encryption.
__________
February 11, 2007 – ‫כ"ג בשבט התשס"ז‬
4394
]22[]12[
‫תכשירים המכילים דקסטרין למניעת‬
‫הדבקות עקב ניתוח‬
]45[
DEXTRIN-CONTAINING
COMPOSITION FOR
PREVENTING SURGICAL
ADHESIONS
]11[
]32[
13.05.1999
9810127.2
]31[ 13.05.1998
111123
2021322000
Int. Cl.8 A61K 031/721
INNOVATA PLC, UNITED
KINGDOM
WO/1999/058168
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.BOX 4060,
TEL AVIV 61040
]42[
]12[
]71[
]15[
711601
[57] A composition for preventing or
reducing the incidence of post-operative
adhesions in or associated with a body
cavity comprising an aqueous formulation
containing the polysaccharide dextrin in an
amount effective to prevent or reduce such
adhesions, wherein the dextrin contains
]33[
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,0323 .‫ד‬.‫ ת‬, 66 ‫רחוב אחד העם‬
more than 15% of polymers with a degree
of polymerization (DP) greater than 12 and
acts as an osmotic agent to maintain a
volume of the aqueous formulation in the
body cavity serving to separate tissues
which otherwise may adhere to each other.
__________
4395
GB
US
]22[]12[
711118
– ‫ – אתיל‬6( – 2 – )‫ – דימתילאתיל‬6 ,6( – 9
– )‫ – אילמתוקסי‬0 – ‫ – טריאזול‬H – 1, 2, 46
‫ – טריאזולו‬0 ,6 ,6–)‫ – פלואורופניל‬6( – 0
‫ תהליכים להכנתו‬,‫] פירידאזין‬b – 0 ,0[
‫ותכשירי רוקחות המכילים אותו‬
]45[
7 - (1, 1 - DIMETHYLETHYL) - 6 (2 - ETHYL - 2H - 1, 2, 4 - TRIAZOL
- 3 YLMETHOXY) - 3 - (2 FLUOROPHENYL) - 1, 2, 4 TRIAZOLO [4 , 3 -B] PYRIDAZINE,
PROCESSES FOR ITS
PREPARATION AND
PHARMACEUTICAL
COMPOSITION COMPRISING IT
]11[
]32[
]42[
15.06.1999
9813576.7
]31[ 24.06.1998
]33[ GB
Int. Cl.8 A61K 031/5025, A61P 001/00, 003/00, 021/00, 025/00, 029/00, C07D
487/04
MERCK SHARP & DOHME LTD,
UNITED KINGDOM
WO/1999/067245
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל אביב‬,0323 .‫ד‬.‫ ת‬, 66 ‫רחוב אחד העם‬
P.O.BOX 4060,
TEL AVIV 61040
]12[
]71[
]15[
[57] 7-(1, 1-Dimethylethyl)-6-(2-ethyl2H-1,2,4-triazol-3-ylmethoxy)-3-(2-
fluorophenyl)-1,2,4-triazolo[4,3-b]
pyridazine of the formula
__________
February 11, 2007 – ‫כ"ג בשבט התשס"ז‬
4396
]22[]12[
]45[
APPARATUS FOR APPLYING
CYCLIC PACING AT AN
AVERAGE RATE JUST ABOVE
THE INTRINSIC HEART RATE
]11[
]32[
]42[
]12[
]71[
]15[
21.05.1999
09/084571
]31[ 26.05.1998
Int. Cl.8 A61N 001/36
MORTON M. MOWER, U.S.A.
WO/1999/061101
JEREMY M. BEN-DAVID & CO.
LTD.,
HAR HOTZVIM HI-TECH PARK,
P.O. BOX 45087,
JERUSALEM 91450
[57] An implantable cardiac stimulator
(810) to perform pacing of a heart, the
heart having an intrinsic atrial firing rate,
the cardiac stimulator comprising: plural
electrodes (815, 817) adapted to applying
pacing stimuli to the heart; and pulse
generation circuitry (844) connected to the
plural electrodes and adapted to generate
electrical pulses as biphasic pacing stimuli,
wherein the biphasic stimulation comprises
an anodal stimulation phase followed by a
711106
‫התקן ליישום קיצוב מחזורי בקצב ממוצע‬
‫גבוה במעט מקצב הלב הטבעי‬
]33[
,‫דוד ושות' בע"מ‬-‫ בן‬.‫ירמיהו מ‬
‫ ירושלים‬,07319 .‫ד‬.‫ ת‬, ‫הר חוצבים‬
cathodal stimulation phase; wherein a
series of pacing stimuli (852) are applied
to at least one ventricle having an initial
pacing rate, the initial pacing rate being
slightly greater than the intrinsic atrial
firing rate, and wherein the pacing rate is
decreased over time from the initial pacing
rate to a minimum pacing rate that is
slightly less than the intrinsic atrial firing
rate.
__________
4397
US
]22[]12[
711016
‫שיטה לאיסוף ולהכנה ראשונית של דגימת‬
‫ריקמה עבור אבחון גנטי מולקולרי‬
]45[
DEVICE AND METHOD FOR
COLLECTION AND INITIAL
PREPARATION OF TISSUE
SAMPLES FOR MOLECULAR
GENETIC DIAGNOSTICS
]11[
]42[
]12[
]11[
]71[
]15[
25.05.1998
Int. Cl.8 C12Q 001/68, G01N 001/08, 033/12
AGROBIOGEN GMBH, GERMANY
BREM GOTTFRIED
WO/1999/061882
DR. MARK FRIEDMAN LTD.,
,‫ד"ר מרק פרידמן ושות‬
BEIT SAMUELOFF, 7 HAOMANIM
‫ תל אביב‬,9 ‫בית שמואלוב רח' האומנים‬
STREET
TEL AVIV
[57] A device for collecting and initially
preparing samples comprising DNA
containing cells from an animal,
comprising a sample receiving container
(1), and sample collecting means (4),
which means enters the sample receiving
container after collecting the sample and
tightly seals it, wherein the sample
receiving container has a base (2) and side
walls (3), has on the container's side walls,
in an area removed from the base, means
(5) for securing the introduced sample
collecting means, and is provided with an
easily penetrable lid, and provided in the
container are means to protect from DNAdegrading enzymes, and wherein the
sample collecting means (4) is made in
such a way that in one step the sample is
collected and introduced into the sample
receiving container, and that it one entry
into the sample receiving container is fixed
February 11, 2007 – ‫כ"ג בשבט התשס"ז‬
in place by the means (5) for securing and
divides the sample receiving container into
at least one sample space (6, 6a), which is
limited by the base and the side walls of
the sample receiving container and the
front end of the sample collecting means,
and wherein the sample receiving
container is associated with an ear tag,
which is provided with a means of
verifying identity and comprising an
apertures plate and a spike plate, and
which may be used for the identification of
an animal, wherein the sample collection
container is releasably connected with the
aperture plate of the ear tag and is
provided with the same means of verifying
identity as the ear tag, and wherein the
sample collecting means is releasably
connected with the spike plate of the ear
tag.
4398
__________
]22[]12[
776777
‫ של תוכן‬TIC ‫התאמה אישית מסוג‬
‫אלקטרוני המבוסס על פירוש בצד‬
‫המשתמש לדוחות און–ליין עם מודלים‬
‫היירארכיאלים של תכונות הצרכן בכדי‬
‫להכוונת תו‬
]45[
TIC CUSTOMIZATION OF
ELECTRONIC CONTENT BASED
ON USER SIDE
INTERPRETATION OF ONLINE
REPORTS WITH
HIERARCHICAL MODELS OF
CONSUMER ATTRIBUTES
]11[
]32[
07.07.1999
60/091979
]31[ 07.07.1998
]33[ US
134221
1121222000
US
152452
1221122000
US
Int. Cl.7 G06F 017/30, G06Q 003/00000
ENCIRQ CORPORATION, U.S.A.
WO/2000/002112
SANFORD T.COLB & CO.,
,,'‫ קולב ושות‬.‫סנפורד ט‬
P.O.B. 2273,
‫ רחובות‬,6690 .‫ד‬.‫ ת‬, ‫ מרמורק‬,0 ‫שער הגיא‬
REHOVOT
]42[
]12[
]71[
]15[
[57] A method of customizing a
structured document delivered
electronically to a consumer computer, the
consumer computer including a display
device, the method comprising: receiving a
structured document at the consumer
computer, the structured document
including a plurality of variable content
sections, each variable content section
having a plurality of selectable content
alternatives; for each variable content
4399
section, selecting a subset of the content
alternatives for augmenting the section by
evaluating the content alternatives with
respect to a consumer profile of the
consumer, ordering the subset of content
alternatives into an order including a first
content alternative, and augmenting the
section with the first content alternative;
presenting the augmented structured
document to the consumer on the display
device with the first content alternative for
each variable content section; and enabling
retrieval of the remaining content
alternatives for each variable content
section; and enabling retrival of the
remaining content alternatives for each
variable content section.
__________
]22[]12[
]45[
HIGH THROUGHPUT SCREEN
]11[
]32[
]42[
]12[
14.06.1999
9812783.0
]31[ 12.06.1998
Int. Cl.8 G01N 033/483, 033/543
XENTION DISCOVERY LIMITED,
UNITED KINGDOM
WO/1999/066329
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.BOX 4060,
TEL AVIV 61040
]71[
]15[
[57] A structure comprising a biological
membrane (2) adhered with a high
February 11, 2007 – ‫כ"ג בשבט התשס"ז‬
776711
‫מסך סינון בעל קיבולת גבוהה‬
]33[
GB
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,0323 .‫ד‬.‫ ת‬, 66 ‫רחוב אחד העם‬
resistance seal to a porous or perforated
substrate (4) for use in a high throughput
4400
screening process, wherein said substrate
has pores of diameters between 0.5 μm and
10 μm, and wherein the biological
membrane comprises an ion channel or
transporter and said substrate is disposed
between said membrane and a solution
perfusion channel.
__________
]22[]12[
]45[
INTERACTIVE SEARCHING
SYSTEM AND METHOD
]11[
]42[
]12[
]11[
11.12.2000
Int. Cl.8 G06F 017/30
CELEBROS LTD.
OREN HOD, ASSAF ROTH, HAREL
BROWN, TAL RUBENCZYK
]15[
G.E. EHRLICH (1995) LTD.,
AYALON TOWER 15TH FLOOR
11 MENACHEM BEGIN STREET
52521 RAMAT GAN
[57] An interactive method for searching
a database to produce a refined results
space, the method comprising: analyzing
for user-input search criteria, searching
said database using said user-input search
criteria to obtain an initial result space,
4401
776677
‫מערכת ושיטה לחיפוש אינטראקטיבי‬
‫ הרצליה פיתוח‬,‫סלברוס בע"מ‬
‫ טל‬,‫ הראל בראון‬,‫ אסף רוט‬,‫אורן הוד‬
‫רובנצ'יק‬
,‫) בע"מ‬6777( ‫ארליך‬.‫אי‬.‫ג'י‬
,66 ‫ רחוב מנחם בגין‬67 ‫מגדל אילון קומה‬
‫רמת גן‬
obtaining user input to restrict said initial
results space, thereby to obtain said refined
results space, and generating at least one
segmenting prompt for said obtaining user
input, said at least one prompt having a
plurality of potential answers, said answers
being selected to divide said initial results
space, each answer corresponding to a part
of said results space, each part of said
results space comprising a substantially
proportionate share of said results space.
__________
February 11, 2007 – ‫כ"ג בשבט התשס"ז‬
4402
]22[]12[
776606
‫הרכבים רוקחיים לפעילות אנטאגוניסתית‬
‫ושיטות לזיהוי חומרים מתנגדים לערוצי‬
‫סידן‬
]45[
PHARMACEUTICAL
COMPOSITIONS FOR
ANTAGONIZING ACTIVITY AND
METHODS FOR IDENTIFICATION
OF CALCIUM CHANNEL
ANTAGONIZERS
]11[
]32[
]42[
30.06.1999
09/107037
]31[ 30.06.1998
]33[ US
Int. Cl.8 A61K 031/445, 031/495, 031/535, A61P 009/00, 025/00, 025/04, C07D
211/14, 211/36, 295/04, 401/04
NEUROMED TECHNOLOGIES, INC.,
CANADA
WO/2000/001375
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל אביב‬,0323 .‫ד‬.‫ ת‬, 66 ‫רחוב אחד העם‬
P.O.BOX 4060,
TEL AVIV 61040
]12[
]71[
]15[
[57] A pharmaceutical composition for
use in treating conditions characterized by
calcium channel activity which
composition comprises, in admixture with
a pharmaceutically acceptable excipient, a
dosage amount of a compound of the
formula
wherein m is 0, 1 or 2;
wherein when m is 0, Z is O, when m is 1,
Z is N, and when m is 2, Z is C; Y, H, OH,
NH2, or an organic moiety of 1-20C,
optionally additionally containing 1-9
heteroatoms selected from the group
consisting of N, P, O, S and halo; each 11
and 12 is independently 0-5; 13 is 0 or 1;
each of R1, R2 and R3 is independently
alkyl (1-6C), aryl (6-10C) or arylalkyl (716C) optionally containing 1-4
heteroatoms selected from the group
consisting of halo, N, P, O, and S or each
of R1 and R2 may independently be halo,
COOR, CONR2, CF3, CN or NO2, wherein
R is H or alkyl (1-6C); n is 0 or 1; X is a
linker; with the proviso that Y is not a
tropolone, a coumarin, or an antioxidant
containing an aromatic group and with the
further proviso that if 13 is 0, neither R1
nor R2 can be F in the para position.
4403
__________
]22[]12[
777676
‫שיטה להכנת אתיל אסטר של חומצה‬
‫אטרופית‬
]45[
METHOD FOR PRODUCING
ATROPIC ACID ETHYL ESTER
]11[
]32[
]42[
]12[
28.07.1999
19836222.6
]31[ 11.08.1998
]33[ DE
Int. Cl.8 C07C 067/343, 069/00, 069/618
ABBOTT GMBH & CO. KG,
GERMANY
WO/2000/009469
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל אביב‬,0323 .‫ד‬.‫ ת‬, 66 ‫רחוב אחד העם‬
P.O.BOX 4060,
TEL AVIV 61040
]71[
]15[
[57] A process for preparing ethyl
atropate with a methyl ester content not
exceeding 0.05% by reacting ethyl
phenylacetate with paraformaldehyde in
the presence of a base, wherein the product
employed as ethyl phenylacetate contains
not more than 0.03% of the corresponding
methyl phenylacetate, and wherein the
reaction is carried out with only one base
in N-methylpyrrolidone or N,Ndimethylformamide.
__________
]22[]12[
]45[
APPARATUS AND REACTOR FOR
GENERATING AND FEEDING
HIGH PURITY MOISTURE
]11[
]32[
21.07.2000
11-223548
]31[ 06.08.1999
22-337771
3122222000
Int. Cl.8 C01B 005/00
TADAHIRO OHMI, JAPAN
FUJIKIN INCORPORATED, JAPAN
]42[
]12[
]71[
]15[
WO/2001/010774
WOLFF, BREGMAN AND GOLLER,
19B KEREN HAYESOD ST.
P.O.B. 1352,
JERUSALEM 91013
February 11, 2007 – ‫כ"ג בשבט התשס"ז‬
777717
‫התקן ומגוב לחילול והזנת לחות בעלת‬
‫רמת טיהור גבוהה‬
]33[
JP
JP
,‫ ברגמן וגולר‬,‫וולף‬
‫ ירושלים‬,6076 .‫ד‬.‫ ת‬, '‫ב‬67 ‫רחוב קרן היסוד‬
4404
[57] An apparatus for generating and
feeding moisture, comprising: a reactor
having an upstream gas inlet side, a
downstream moisture outlet side and a
catalyst for generating moisture from
hydrogen and oxygen, wherein the reactor
generates moisture from hydrogen and
oxygen by catalytic reaction at a
temperature of not higher than 450oC;
means for reducing pressure provided on
the downstream side of the reactor, and
disposed so that moisture leaving and fed
from said reactor is reduced in pressure by
the means for reducing pressure while an
internal high pressure in the reactor is
maintained, wherein the means for
reducing pressure comprises one or more
components selected from the group
consisting of an orifice, a valve, a capillary
and a filter;
a first reactor structural component having
a material gas supply joint defining a
material gas supply passage; a second
reactor structural component having a
moisture gas take-out joint defining a
moisture outlet passage, wherein the first
reactor structural component and the
second reactor structural component are
mated to form a reactor shell having an
interior space and wherein the second
reactor structural component defines an
inside wall surface; a first reflector
disposed in the interior space to face the
material gas supply passage; a second
reflector disposed in the interior space to
face the moisture outlet passage, wherein
the first reflector and the second reflector
are identical flat plates symmetrically
disposed in the interior space, wherein the
catalyst comprises a platinum coated
catalyst layer provided on the inside wall
surface of the second reactor structural
component, a process chamber, wherein
the reactor is connected to feed moisture
gas to the process chamber, wherein the
moisture gas fed into the process chamber
is reduced in pressure by the means for
reducing pressure, wherein the first
reflector and the second reflector each
include a peripheral portion inclined in
cross-section, and the diameters of the first
reflector and the second reflector should be
larger than approximately 70% of the
internal diameters of the reactor structural
components.
__________
4405
]22[]12[
]45[
CHARACTER RECOGNITION
]11[
]32[
]42[
]12[
]71[
]15[
25.08.1999
9802832-7
]31[ 26.08.1998
Int. Cl.8 G06K 009/00
ZI DECUMA AB, SWEDEN
WO/2000/013131
EITAN, PEARL, LATZER AND
COHEN ZEDEK,
P.O.B. 12688,
HERZLIYA 46733
[57] A method for character recognition
comprising the steps of: detecting a
separate character or a character in a
composition of characters, preprocessing
the character, comparing the preprocessed
character with one or more template
symbols, and applying a decision rule in
order to either reject a template symbol or
decide that the template symbol is included
in the character, the step of preprocessing
the character comprising the steps of:
777617
‫זיהוי סימנים‬
]33[
SE
,‫ לצר וכהן צדק‬,‫ פרל‬,‫איתן‬
‫ הרצליה‬,66211 .‫ד‬.‫ ת‬, 9 ‫רחוב שנקר‬
representing the character as one or more
curves, said representation being shaped to
allow quantitative comparison, and
parameterising said curve or curves,
characterised in that the step of
preprocessing the character further
comprises the step of forming, regarding
various classes of transformations, one or
more shapes for said curve or curves,
wherein said one or more shapes for said
curve or curves are defined as
d(Φ)={ψ/ ψ = g (Φ), g ε G},
where Φ is said parameterized curve, d (Φ)
is said shape for said curve, and G is said
class of transformations, said shape being
invariant with respect to said class of
transformations, and that the step of
comparing comprises the steps of: forming
one or more geometric proximity
measures, determining for every shape the
values of said geometric proximity
measures between said shape and correspondingly determined shapes for the
template symbols, and that the step of
applying a decision rule comprises the step
of: selecting one or more template symbols
in consideration of said values.
__________
February 11, 2007 – ‫כ"ג בשבט התשס"ז‬
4406
]22[]12[
]45[
ACTIVE INGREDIENT SUPPORT
IN THE FORM OF A FILM
]11[
]32[
]42[
]12[
31.07.1999
19837073.3
]31[ 17.08.1998
Int. Cl.8 A61K 009/00, 009/20, 009/70
LTS LOHMANN THERAPIESYSTEME AG, GERMANY
WO/2000/010539
DR. YITZHAK HESS & PARTNERS,
279 HAYARKON STREET
P.O.B. 6451
TEL AVIV 61063
]71[
]15[
[57] Film-shaped active substance carrier
for controlled release of active substance,
comprising a carrier film to the surface of
which particles of an active substancecontaining substrate are fixedly connected
or into the surface of which the said
particles are embedded, as well as a further
film-shaped layer covering the said carrier
film, which carrier film is enriched with
active substance particles, the said further
film-shaped layer being water vapordiffusible, and the said carrier film and the
said further film shaped layer being sealed
on top of one another in their edge contour
777111
‫רכיב תמיכה פעיל בדמות של סרט צילום‬
]33[
,‫ עו"פ‬,‫ד"ר יצחק הס ושותפיו‬
‫ תל אביב‬,2076 .‫ד‬.‫ ת‬, 697 ‫רחוב הירקון‬
such that the film-shaped active substance
carrier is configured as a pouch in whose
interior space there are gas-forming
components, characterized in that in the
cavity of the active substance carrier there
is contained at least one further filmshaped body on whose surface there are
located active substance-containing
particles which are fixedly connected with
the said film-shaped body, and/or that in
the said cavity there are additional filmshaped bodies which are configured as
active substance carriers for the generation
of gas.
__________
4407
DE
]22[]12[
777868
–6,6,0,0–‫–קרבוקסיאמינו‬0
‫טטרההידרוקוינולינים המותמרים בעמדה‬
CETP ‫ כמעכבים של‬6
]45[
4-CARBOXYAMINO-2SUBSTITUTED-1,2,3,4TETRAHYDROQUINOLINES AS
CETP INHIBITORS
]11[
]32[
]42[
]12[
]71[
]15[
10.09.1999
60/100860
]31[ 17.09.1998
]33[ US
Int. Cl.8 A61K 031/47, A61P 003/06, C07D 215/42, 409/00
PFIZER PRODUCTS, INC., U.S.A.
WO/2000/017164
LUZZATTO & LUZZATTO,
,‫לוצאטו את לוצאטו‬
INDUSTRIAL PARK, OMER
‫ באר שבע‬,7076 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
P.O.B 5352
BEER-SHEVA 84152
The applications for division
from this application have
not yet been published
,815565
‫בקשות חלוקה מבקשה זו‬
.‫שטרם פורסמו‬
[57] A compound of the formula
a prodrug thereof, or a pharmaceutically
acceptable salt of said compound or of said
prodrug; wherein R1 is Y, W-X or W-Y;
wherein W is a carbonyl, thiocarbonyl,
sulfinyl or sulfonyl;
X is –O-Y, -S-Y, -N(H)-Y or –N-(Y)2;
wherein Y for each occurrence is
independently Z or a fully saturated,
partially unsaturated or fully unsaturated
one to ten membered straight or branched
carbon chain wherein the carbons, other
than the connecting carbon, may optionally
be replaced with one or two heteroatoms
February 11, 2007 – ‫כ"ג בשבט התשס"ז‬
selected independently from oxygen, sulfur
and nitrogen and said carbon is optionally
mono-, di- or tri-substituted independently
with halo, said carbon is optionally monosubstituted with hydroxy, said carbon is
optionally mono-substituted with oxo, said
sulfur is optionally mono- or disubstituted with oxo, said nitrogen is
optionally mono-, or di-substituted with
oxo, and said carbon chain is optionally
mono-substituted with Z; wherein Z is a
partially saturated, fully saturated or fully
4408
unsaturated three to eight membered ring
optionally having one to four heteroatoms
selected independently from oxygen, sulfur
and nitrogen, or a bicyclic ring consisting
of two fused partially satuated, fully
saturated or fully unsaturated three to six
membered rings, taken independently,
optionally having one to four heteroatoms
selected independently from nitrogen,
sulfur and oxygen; wherein said Z
substituent is optionally mono-, di- or trisubstituted independently with halo, (C2C6) alkenyl, (C1-C6) alkyl, hydroxy, (C1C6) alkyl, hydroxy, (C1-C6) alkoxy, (C1-C4)
alkylthio, amino, nitro, cyano, oxo,
carboxy, (C1-C6) alkyloxycarbonyl, monoN- or di-N,N-(C1-C6) alkylamino wherein
said (C1-C6) alkyl substituent is optionally
mono-, di- or tri-substituted independently
with halo, hydroxy, (C1-C6) alkoxy, (C1C4) alkylthio, amino, nitro, cyano, oxo,
carboxy, (C1-C6) alkyloxycarbonyl, monoN- or di-N,N-(C1-C6) alkylamino, said (C1C6) alkyl substituent is also optionally
substituted with from one to nine fluorines;
R2 is a partially saturated, fully saturated
or fully unsaturated one to six membered
straight or branched carbon chain wherein
the carbons, other than the connecting
carbon, may optionally be replaced with
one or two heteroatoms selected
independently from oxygen, sulfur and
nitrogen wherein said carbon atoms are
optionally mono-, di- or tri-substituted
independently with halo, said carbon is
optionally mono-substituted with oxo, said
carbon is optionally mono-substituted with
hydroxy, said sulfur is optionally mono- or
di-substituted with oxo, said nitrogen is
optionally having one to two heteroatoms
selected independently from oxygen, sulfur
and nitrogen, wherein said R2 ring is
optionally attached through (C1-C4) alkyl;
wherein said R2 ring is optionally mono-,
di- or tri-substituted independently with
halo, (C2-C6) alkenyl, (C1-C6) alkyl,
hydroxy, (C1-C6) alkoxy, (C1-C4) alkylthio,
amino, nitro, cyano, oxo, carboxy, (C1-C6)
4409
alkyloxycarbonyl, mono-N- or di-N,N-(C1C6) alkylamino wherein said (C1-C6) alkyl
substituent is optionally mono-, di- or trisubstituted independently with halo,
hydroxy, (C1-C6) alkoxy, (C1-C4) alkylthio,
oxo or (C1-C6) alkyloxycarbonyl; with the
proviso that R2 is not methyl; R3 is
hydrogen or Q; wherein Q is a fully
saturated, partially unsaturated or fully
unsaturated one to six membered straight
or branched carbon chain wherein the
carbons other than the connecting carbon,
may optionally be replaced with one
heteroatom selected from oxygen, sulfur
and nitrogen and said carbon is optionally
mono-, di- or tri-substituted independently
with halo, said carbon is optionally monosubstituted with hydroxy, said carbon is
optionally mono-substituted with oxo, said
sulfur is optionally mono- or di-substituted
with oxo, said nitrogen is optionally monoor di-substituted with oxo, and said carbon
chain is optionally mono-substituted with
V;
wherein V is a partially saturated, fully
saturated or fully unsaturated three to eight
membered ring optionally having one to
four heteratoms selected independently
from oxygen, sulfur and nitrogen, or a
bicyclic ring consisting of two fused
partially saturated, fully saturated or fully
unsaturated three to six membered rings,
taken independently, optionally having one
to four heteroatoms selected independently
from nitrogen, sulfur and oxygen; wherein
said V substituent is optionally mono-, di-,
tri-, or tetra-substituted independently with
halo, (C1-C6) alkyl, (C2-C6) alkenyl,
hydroxy, (C1-C6) alkoxy, (C1-C4) alkylthio,
amino, nitro, cyano, oxo, carboxamoyl,
mono-N-or di-N,N-(C1-C6)
alkylcarboxamoyl, carboxy, (C1-C6)
alkyloxycarbonyl, mono-N- or di-N-,N(C1-C6) alkylamino wherein said (C1-C6)
alkyl or (C2-C6) alkenyl substituent is
optionally mono-, di- or tri-substituted
independently with hydroxy, (C1-C6)
alkoxy, (C1-C4) alkylthio, amino, nitro,
cyano, oxo, carboxy, (C1-C6)
alkyloxycarbonyl, mono-N- or di-N,N (C1C6) alkylamino, said (C1-C6) alkyl or (C2C6) alkenyl substituents are also optionally
substituted with from one to nine fluorines;
R4 is Q1 or V1;
wherein Q1 is a fully saturated, partially
unsaturated or fully unsaturated one to six
membered straight or branched carbon
chain wherein the carbons, other than the
connecting carbon, may optionally be
replaced with one heteroatom selected
from oxygen, sulfur and nitrogen and said
carbon is optionally mono-, di- or trisubstituted independently with halo, said
carbon is optionally mono-substituted with
hydroxy, said carbon is optionally monosubstituted with oxo, said sulfur is
optionally mono- or di-substituted with
oxo, said nitrogen is optionally mono- or
di-substituted with oxo, and said carbon
chain is optionally mono-substituted with
V1; wherein V1 is a partially saturated,
fully saturated or fully unsaturated three to
six membered ring optionally having one
to two heteroatoms selected independently
from oxygen, sulfur and nitrogen;
wherein said V1 substituent is optionally
mono-, di-, tri-, or tetrasubstituted
independently with halo, (C1-C6) alkyl,
(C1-C6) alkoxy, amino, nitro, cyano, (C1C6) alkyloxycarbonyl, mono -N-or di-N,N(C1-C6) alkylamino wherein said (C1-C6)
alkyl substituent is optionally monosubstituted with oxo, said (C1-C6) alkyl
substituent is also optionally substituted
with from one to nine fluorines;
wherein either R3 must contain V or R4
must contain V1; R5, R6, R7 and R8 are
each independently hydrogen, a bond, nitro
or halo wherein said bond is substituted
with T or a partially saturated, fully
saturated or fully unsaturated (C1-C12)
straight or branched carbon chain wherein
carbon may optionally be replaced with
one or two heteroatoms selected
independently from oxygen, sulfur and
nitrogen wherein said carbon atoms are
February 11, 2007 – ‫כ"ג בשבט התשס"ז‬
optionally mono-, di- or tri-substituted
independently with halo, said carbon is
optionally mono-substituted with hydroxy,
said carbon is optionally mono-substituted
with oxo, said sulfur is optionally monoor di-substituted with oxo, said nitrogen is
optionally mono- or di-substituted with
oxo, and said carbon is optionally monosubstituted with T; wherein T is a partially
saturated, fully saturated or fully
unsaturated three to eight membered ring
optionally having one to four heteroatoms
selected independently from oxygen, sulfur
and nitrogen, or, a bicyclic ring consisting
of two fused partially saturated, fully
saturated or fully unsaturated three to six
membered rings, taken independently,
optionally having one to four heteroatoms
selected independently from nitrogen,
sulfur and oxygen; wherein said T
substituent is optionally mono-, di or trisubstituted independently with halo, (C1C6) alkyl, (C2-C6) alkenyl, hydroxy, (C1C6) alkoxy, (C1-C4) alkylthio, amino, nitro,
cyano, oxo. carboxy, (C1-C6)
alkyloxycarbonyl, mono-N- or di-N,N,(C1-C6) alkylamino wherein said (C1-C6)
alkyl substituent is optionally mono-, di- or
tri-substituted independently with hydroxy,
(C1-C6) alkoxy, (C1-C4) alkylthio, amino,
nitro, cyano, oxo, carboxy, (C1-C6)
alkyloxycarbonyl, mono-N- or di-N,N,N(C1-C6) alkylamino, said (C1-C6) alkyl
substituent is also optionally substituted
with from one to nine fluorines; and
wherein R5 and R6, or R6 and R7, and/or R7
and R8 may also be taken together and can
form at least one four to eight membered
ring that is partially saturated or fully
unsaturated optionally having one to three
heteroatoms independently selected from
nitrogen, sulfur and oxygen; wherein said
ring formed by R5 and R6, or R6 and R7,
and/or R7 and R8 are optionally mono-, dior tri-substituted independently with halo,
(C1-C6) alkyl, (C1-C4) alkylsulfonyl, (C2C6) alkenyl, hydroxy, (C1-C6) alkoxy, (C1C4) alkylthio, amino, nitro, cyano, oxo,
4410
carboxy, (C1-C6) alkyloxycarbonyl, monoN- or di-N,N-(C1-C6) alkylamino wherein
said (C1-C6) alkyl substituent is optionally
mono-, di- or tri-substituted independently
with hydroxy, (C1-C6) alkoxy, (C1-C4)
alkylthio, amino, nitro, cyano, oxo,
carboxy, (C1-C6) alkyloxycarbonyl, monoN- or di-N,N-(C1-C6) alkylamino, said (C1C6) alkyl substituent is also optionally
substituted with from one to nine fluorines.
__________
]22[]12[
]45[
ELECTROLYTIC CAPACITORS
AND METHOD FOR MAKING
THEM
]11[
]42[
]12[
]11[
]15[
22.02.2001
Int. Cl.8 H01G 009/00
ACKTAR LTD.
ZVI FINKELSTEIN, DINA KATSIR
JEREMY M. BEN-DAVID & CO.
LTD.,
HAR HOTZVIM HI-TECH PARK,
P.O. BOX 45087,
JERUSALEM 91450
[57] A method for making at least one
electrolytic capacitor, integrated with a
substrate adapted to carry integrated circuit
components, wherein said substrate is
coated with at least one sequence of each
of the following layers: a vacuum
deposited film having a high specific
surface area, which is selected from the
group consisting of valve metals and
mixtures of valve metals with valve metal
777816
‫קבלים אלקטרוליטיים ושיטה לייצורם‬
‫ קרית גת‬,‫אקטר בע"מ‬
‫ דינה קציר‬,‫צבי פינקלשטיין‬
,‫דוד ושות' בע"מ‬-‫ בן‬.‫ירמיהו מ‬
‫ ירושלים‬,07319 .‫ד‬.‫ ת‬, ‫הר חוצבים‬
oxides; superimposed on said film having
a high specific surface area, at least one
dielectric film comprising a substance
selected from the group consisting of valve
metal oxides, their complex oxides with at
least one rare earth metal and their
complex oxides with at least one alkaline
earth metal; and a solid electrolyte film
superimposed on said at least one film.
__________
4411
]22[]12[
777087
‫מזרק ושיטה לשימוש בו בבדיקה‬
]45[
SYRINGE AND METHOD FOR
ITS UTILIZATION IN ANALYSIS
]11[
]42[
]12[
]15[
26.02.2001
Int. Cl.8 A61B 005/15, A61M 001/02, 005/00, B01L 003/14
‫ מגדל העמק‬,‫אריטרוסב בע"מ‬
WOLFF, BREGMAN AND GOLLER,
,‫ ברגמן וגולר‬,‫וולף‬
19B KEREN HAYESOD ST.
‫ ירושלים‬,6076 .‫ד‬.‫ ת‬, '‫ב‬67 ‫רחוב קרן היסוד‬
P.O.B. 1352,
JERUSALEM 91013
[57] A syringe (2) for preventing anemia
resulting from withdrawal of blood from a
patient for analysis, said syringe
comprising: a syringe body (4) having, at
its lower end, a nozzle to which means for
connection to a patient's blood vessel are
attachable: a hollow, cylindrical piston rod
(10) having an inner bottom surface and
being slidably disposed in said syringe
body and carrying, at its lower end, a
piston sealingly fitting said body, said
piston rod having a gripping disk at its
upper end; a plasma vessel (28) disposed
within and slidingly fitting said hollow
piston rod, the lower end of said vessel
being closed and carrying a hollow needle
(8) through which a liquid can enter said
vessel via said hollow needle; a helical
compression spring surrounding said
February 11, 2007 – ‫כ"ג בשבט התשס"ז‬
needle and positioned between said plasma
vessel and said inner bottom surface of
said piston rod; wherein, by pulling up said
piston rod, whole blood from said patient
is drawn into said syringe body, said whole
blood then being separated by centrifuging
into a plasma component and a packedcells component, and wherein,
subsequently, by applying force to the
upper, protruding end of said plasma
vessel, said hollow needle is caused to
perforate said piston, whereupon pushing
down said piston rod causes said separate
plasma component to be forced through
said needle into said plasma vessel,
whereinafter, when ceasing to apply said
force to said end, said hollow needle is
withdrawn from said piston by the
restoring force of said spring.
4412
__________
]22[]12[
]45[
ULTRASONIC POSITIONING
]11[
]42[
]12[
]11[
26.02.2001
Int. Cl.8 A61B 006/00, 008/12
MEDIGUS LTD.
MENASHE SONNENSCHEIN,
ELAZAR SONNENSCHEIN
LUZZATTO & LUZZATTO,
INDUSTRIAL PARK, OMER
P.O.B 5352
BEER-SHEVA 84152
]15[
[57] Endoscopic device comprising a
system for measuring the distance between
and/or the relative alignment of two
objects located at two different locations
along the length of said endoscope
comprising elements chosen from the
group consisting of:
(a) transducers (51, 52) and
(b) reflectors (55);
wherein said elements are located on said
endoscope in one of the following
arrangements:
(a) one or more transducers or arrays of
transducers, functioning as transmitters of
4413
777008
‫קביעת מיקום באמצעות אולטראסאונד‬
‫ עומר‬,‫מדיגוס בע"מ‬
‫ אלעזר זוננשיין‬,‫מנשה זוננשיין‬
,‫לוצאטו את לוצאטו‬
‫ באר שבע‬,7076 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
ultrasonic signals, are located on, or near,
one of said objects and one or more
transducers or arrays of transducers,
functioning as receivers of said ultrasonic
signals, are located on, or near, the other of
said objects; or
(b) the arrangement of (a) wherein, at least
one of the transducers or arrays of
transducers, functioning as receivers of
ultrasonic signals, is replaced by a reflector
and at least one of the transducers or arrays
of transducers, functioning as transmitters
of said ultrasonic signals, also functions as
a receiver of said signals.
__________
]22[]12[
777066
‫שיטה ומערכת לחקיה של סביבת שמע‬
‫תלת–מימדית‬
]45[
METHOD AND SYSTEM FOR
SIMULATING A 3D SOUND
ENVIRONMENT
]11[
]42[
]12[
]11[
05.03.2001
Int. Cl.8 H04R 005/033, H04S 001/00, 003/00
BE4 LTD.
‫ רחובות‬,‫ בע"מ‬0‫בי‬
HAIM LEVY, YUVAL COHEN,
‫ גיורא נוה‬,‫ אמיר בר און‬,‫ יובל כהן‬,‫חיים לוי‬
AMIR BAR ON, GIORA NAVEH
WOLFF, BREGMAN AND GOLLER,
,‫ ברגמן וגולר‬,‫וולף‬
19B KEREN HAYESOD ST.
‫ ירושלים‬,6076 .‫ד‬.‫ ת‬, '‫ב‬67 ‫רחוב קרן היסוד‬
P.O.B. 1352,
JERUSALEM 91013
]15[
[57] A method for simulating a 3D sound
environment in an audio system using an at
least two-channel reproduction device, said
method comprising: generating first and
second pseudo head-related transfer
function (HRTF) data, first using at least
one sound transducer located at the
simulated position and then using at least
two other transducers; dividing a first and
second frequency representation of said
data or using a deconvolution operator on
the time domain representation of said first
and second data, or subtracting the
cepstrum representation of said first and
February 11, 2007 – ‫כ"ג בשבט התשס"ז‬
second data, and using the results of said
division or subtraction to prepare filters
having an impulse response operable to
initiate natural sounds of a remote
transducer for preparing at least two filters
connectable to said system in the audio
path from an audio source to sound
reproduction devices to be used by a
listener, characterized in that said at least
one sound transducer is located at the
simulated 3D sound environment and said
at least two other transducers are located at
the reproduction positions.
4414
__________
]22[]12[
]45[
SPECTRAL BIO-IMAGING DATA
FOR CELL CLASSIFICATION
USING INTERNAL
REFERENCE
]11[
]32[
]42[
]12[
10.09.1999
157138
]31[ 18.09.1998
Int. Cl.8 G01N 001/30, G06K 009/62
APPLIED SPECTRAL IMAGING
LTD.
]71[
]15[
WO/2000/017808
G.E. EHRLICH (1995) LTD.,
AYALON TOWER 15TH FLOOR
11 MENACHEM BEGIN STREET
52521 RAMAT GAN
[57] A method of spectral-morphometric
analysis of biological samples, the
biological samples including substantially
constant components and suspected
variable components, the method
comprising the steps of:
(a) using a spectral data collection device
for collecting spectral data of picture
elements of the biological samples;
(b) defining a spectral vector associated
with picture elements representing a
constant component of at least one of the
biological samples;
4415
777166
‫הדמייה ספקטרלית לסווג תאים בשימוש‬
‫ברפרנס פנימי‬
]33[
US
‫ מגדל‬,‫אפלייד ספקטרל אימג'ינג בע"מ‬
‫העמק‬
,‫) בע"מ‬6777( ‫ארליך‬.‫אי‬.‫ג'י‬
,66 ‫ רחוב מנחם בגין‬67 ‫מגדל אילון קומה‬
‫רמת גן‬
(c) using said spectral vector for defining a
correcting function being selected such
that when operated on spectral vectors
associated with picture elements
representing other constant components,
spectral vectors of said other constant
components are modified to substantially
resemble said spectral vector;
(d) operating said correcting function on
spectral vectors associated with at least
said variable components for obtaining
corrected spectral vectors thereof; and
(e) classifying said corrected spectral
vectors into classification groups.
__________
]22[]12[
]45[
CONTROLLED RELEASE LIQUID
DELIVERY COMPOSITIONS
WITH LOW INITIAL DRUG
BURST
]11[
]32[
]42[
]12[
28.10.1999
181355
]31[ 28.10.1998
Int. Cl.8 A61K 009/00
ATRIX LABORATORIES, INC.,
U.S.A.
WO/2000/024374
REINHOLD COHN AND
PARTNERS,
21 AHAD HA'AM ST.,
P.O.BOX 4060,
TEL AVIV 61040
]71[
]15[
[57] A polymeric composition for
forming a controlled release implant within
a body, comprising: an effective amount of
a biocompatible, biodegradable,
thermoplastic base polymer that is
insoluble in aqueous or body fluids; a
biocomplatible, organic solvent that is
soluble in aqueous or body fluid; a
polymeric controlled release additive,
776716
‫תכשירים נוזליים בעלי שיחרור מבוקר‬
‫ושטף תרופות התחלתי נמוך‬
]33[
US
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,0323 .‫ד‬.‫ ת‬, 66 ‫רחוב אחד העם‬
wherein the polymeric controlled release
additive is a poly (lactide-coglycolide)/polyethylene glycol block
copolymer; and a biologically active agent;
wherein the polymeric composition is
capable of forming the controlled release
implant by dissipation or dispersement of
the organic solvent within the body.
__________
February 11, 2007 – ‫כ"ג בשבט התשס"ז‬
4416
]22[]12[
]45[
COMPOSITION AND METHOD
FOR INCREASING PRODUCTION
YIELD OF AGRICULTURALLY
USEFUL SPECIES
]11[
]32[
]42[
]12[
03.11.1999
126874
]31[ 03.11.1998
Int. Cl.8 A61K 038/22
FEDERMAN & SONS (HOLDINGS)
LTD.
NITZAN ZIV, BORIS
SCHWARTZBORD, DANNY
LUXEMBOURG
WO/2000/025831
G.E. EHRLICH (1995) LTD.,
AYALON TOWER 15TH FLOOR
11 MENACHEM BEGIN STREET
52521 RAMAT GAN
]11[
]71[
]15[
[57] A method for increasing the
production yield of an agriculturally useful
species, the method comprising the step of
administering to the species a composition
776871
‫תכשיר ושיטה להגברת תנובתם של זנים‬
‫חקלאיים שימושיים‬
]33[
IL
‫אביב‬-‫ תל‬,‫פדרמן ובניו (אחזקות) בע"מ‬
‫ דני לוקסמבורג‬,‫ בוריס שוורצבורד‬,‫ניצן זיו‬
,‫) בע"מ‬6777( ‫ארליך‬.‫אי‬.‫ג'י‬
,66 ‫ רחוב מנחם בגין‬67 ‫מגדל אילון קומה‬
‫רמת גן‬
containing an effective amount of inhibin
or a fragment thereof, said effective
amount being in a range of from about 20
to about 300 micrograms per dose.
__________
]22[]12[
]45[
4417
IN SITU METHOD OF
ANALYZING CELLS
776801
‫שיטה לבחינת תאים באתר‬
]11[
]32[
]42[
]12[
16.11.1999
196690
]31[ 20.11.1998
Int. Cl.8 G01N 033/53
APPLIED SPECTRAL IMAGING
LTD.
]71[
]15[
WO/2000/031534
G.E. EHRLICH (1995) LTD.,
AYALON TOWER 15TH FLOOR
11 MENACHEM BEGIN STREET
52521 RAMAT GAN
[57] A method of resolving individual
stain images from a biological sample
stained with at least two individual stains,
the method comprising the steps of:
(a) using a spectral data collection device
for collecting spectral data from each pixel
of the biological sample;
(b) calculating a calculated spectrum for
each of said pixels and for each of the at
least two independent stains, said
calculated spectrum being equivalent to an
actual spectrum that would have been
]33[
US
‫ מגדל‬,‫אפלייד ספקטרל אימג'ינג בע"מ‬
‫העמק‬
,‫) בע"מ‬6777( ‫ארליך‬.‫אי‬.‫ג'י‬
,66 ‫ רחוב מנחם בגין‬67 ‫מגדל אילון קומה‬
‫רמת גן‬
measured using said spectral data
collection device had the biological sample
been individually stained with one of the at
least two individual stains;
(c) operating a displaying algorithm on
each of said calculated spectra for
displaying each of said pixels in a
calculated artificial color being equivalent
to an actual color that would have been
perceived for each of said pixels using a
microscope had the biological sample been
individually stained with said one of the at
least two individual stains.
__________
]22[]12[
]45[
APPARATUS AND METHOD FOR
BUILDING MODELING TOOLS
]11[
]32[
]42[
]12[
15.10.1999
60/104682
]31[ 16.10.1998
Int. Cl.8 G06F 009/44, 017/50
COMPUTER ASSOCIATES THINK,
INC., U.S.A.
WO/2000/023883
LUZZATTO & LUZZATTO,
INDUSTRIAL PARK, OMER
P.O.B 5352
BEER-SHEVA 84152
]71[
]15[
[57] An apparatus for building a
modeling tool, comprising: a meta model
including a semantic registry and a meta
data manager; an object/property interface;
February 11, 2007 – ‫כ"ג בשבט התשס"ז‬
776817
‫מיתקן ושיטה לבניית כלי דיגום‬
]33[
US
,‫לוצאטו את לוצאטו‬
‫ באר שבע‬,7076 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
an object/property factory registry coupled
to the meta model and the object/property
interface; and an object/property model
coupled to the object/property interface.
4418
__________
]22[]12[
776068
‫תכשירים ריקומביננטיים לטיפול בשיער‬
]45[
RECOMBINANT HAIR
TREATMENT COMPOSITIONS
]11[
]32[
]42[
]12[
]71[
]15[
15.04.2001
174186
]31[ 16.10.1998
]33[
Int. Cl.7 A61K 000/865000 A61Q 000/50000
MATRIX DESIGN, U.S.A.
WO/2000/023039
SELIGSOHN GABRIELI & CO.,
31 YAVNE ST.
P.O.B. 1426
TEL AVIV 61013
[57] A method of formulating a hair
treatment composition, the method
comprising steps of: providing a human
individual on the basis of that individual
4419
US
,'‫זליגסון גבריאלי ושות‬
‫ תל אביב‬,6062 .‫ד‬.‫ ת‬, 06 ‫רח' יבנה‬
having appealing hair characteristics
obtaining at least one nucleic acid, each of
which encodes a different keratin allelic
variant that is present in hair of the human
individual; introducing each of the at least
one obtained nucleic acids into an
expression vector so that a population of
expression constructs, each of which
encodes at least one keratin allelic variant
is produced; introducing each expression
construct into a host cell so that a
population of host cells, each of which has
received an individual expression construct
and expresses a non-crosslinked keratin
allelic variant therefrom, is produced;
identifying those host cells in the
population of host cells that express one of
the at least one keratin allelic variants in a
manner that does not result in cross-linking
of the at least one produced keratin allelic
variants; purifying each of the at least one
keratin allelic variants from the host cell
that produces them; and combining the
purified keratin allelic variants with one
another and also with components of a hair
treatment composition to form a hair
treatment composition.
__________
]22[]12[
]45[
SPRINKLERS
]11[
]42[
]12[
22.04.2001
Int. Cl.8 B05B 003/02
NAAN IRRIGATION SYSTEMS
(C.S.) LTD.
SANFORD T.COLB & CO.,
P.O.B. 2273,
REHOVOT
]15[
776116
‫ממטירות‬
‫אגודה שיתופית חקלאית בע"מ‬-‫נען השקייה‬
,,'‫ קולב ושות‬.‫סנפורד ט‬
‫ רחובות‬,6690 .‫ד‬.‫ ת‬, ‫ מרמורק‬,0 ‫שער הגיא‬
[57] A rotary sprinkler comprising: a
water inlet (22); a water outlet (28)
arranged for rotation about a rotation axis
(14); a water director (44) associated with
the water outlet; and a watering pattern
determiner (30) associated with at least
one of the water outlet and the water
director and being operative to cause the
sprinkler to have a substantially nonrepeated watering pattern extending over
more than 360 degrees about said rotation
axis, which watering pattern is asymmetric
with respect to said rotation axis, said
asymmetric watering pattern being rotated
for each successive rotation of said water
outlet about said rotation axis with respect
to said watering pattern of the preceding
rotation by a predetermined amount,
whereby successive rotations increase the
angular uniformity of watering about said
rotation axis.
February 11, 2007 – ‫כ"ג בשבט התשס"ז‬
4420
__________